RayKnowChina Research Map
Shortlist0

BeijingChinese PLA General Hospital

Chinese PLA General Hospital

中国人民解放军总医院

Listed for 39 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Chinese PLA General Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌8 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌27 papers led
  3. Hepatocellular carcinoma肝细胞癌184 papers led6 open trials led
  4. Stomach cancer胃癌140 papers led6 open trials led
  5. Hepatoblastoma肝母细胞瘤3 papers led
  6. Retinoblastoma视网膜母细胞瘤2 papers led
  7. Osteosarcoma骨肉瘤12 papers led
  8. Gastrointestinal stromal tumour胃肠道间质瘤7 papers led
  9. Neuroblastoma神经母细胞瘤1 paper led
  10. Ewing sarcoma尤文肉瘤1 paper led
  11. Multiple myeloma多发性骨髓瘤5 papers led2 open trials led
  12. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led6 open trials led
  13. Aplastic anaemia再生障碍性贫血1 paper led1 open trial led
  14. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症2 papers led1 open trial led
  15. Beta thalassaemiaβ 地中海贫血0 papers led
  16. Haemophilia A血友病 A1 paper led
  17. Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征1 paper led
  18. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病12 papers led2 open trials led
  19. IgG4-related diseaseIgG4相关性疾病5 papers led2 open trials led
  20. Myasthenia gravis重症肌无力4 papers led
  21. Moyamoya disease烟雾病46 papers led1 open trial led
  22. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎0 papers led
  23. Takayasu arteritis大动脉炎0 papers led
  24. Hepatic echinococcosis肝包虫病2 papers led
  25. Idiopathic pulmonary fibrosis特发性肺纤维化3 papers led
  26. Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病1 paper led
  27. Amyotrophic lateral sclerosis肌萎缩侧索硬化症20 papers led
  28. Spinal muscular atrophy脊髓性肌萎缩症2 papers led
  29. Fabry disease法布雷病3 papers led
  30. Pompe disease庞贝病1 paper led
  31. Duchenne muscular dystrophy杜氏肌营养不良5 papers led
  32. Behçet disease白塞病0 papers led
  33. Alport syndromeAlport 综合征1 paper led
  34. IgA nephropathyIgA 肾病17 papers led1 open trial led
  35. Gaucher disease戈谢病1 paper led
  36. Osteogenesis imperfecta成骨不全症0 papers led
  37. Primary biliary cholangitis原发性胆汁性胆管炎2 papers led
  38. Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led
  39. Leber hereditary optic neuropathyLeber 遗传性视神经病变1 paper led

Not listed for: Chordoma, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Wilson disease, Biliary atresia, Niemann–Pick disease type C, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 8 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
8
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 2220232024: 1120242025: 222025

5 hospitals in Beijing for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRadiotherapy techniqueSide effects & quality of lifeImaging & AI
Departments in papersRadiation oncologyENT / head & neck surgery
Papers it led8
  1. CircCGNL1 Suppresses Nasopharyngeal Carcinoma Progression by Targeting IGF2BP3 and Inhibiting AKT/mTOR Signaling.2025Journal of biochemical and molecular toxicology
  2. Cutaneous metastasis secondary to nasopharyngeal carcinoma: a case report.2025World journal of surgical oncologyFree full text
  3. The impact of submandibular glands protection on xerostomia as monitored by diffusion-weighted imaging in nasopharyngeal carcinoma patients.2024Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  4. Prognostic factor analysis in patients with early-stage nasopharyngeal carcinoma in the USA.2023Future oncology (London, England)
  5. Development and validation of a nomogram for prediction of recovery from moderate-severe xerostomia post-radiotherapy in nasopharyngeal carcinoma patients.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  6. Sparing submandibular gland to alleviating acute xerostomia in patients with nasopharyngeal carcinoma treated with helical tomotherapy: Evaluation by diffusion kurtosis imaging.2022Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  7. The Acute Toxicities and Efficacy of Concurrent Chemotherapy With Docetaxel Plus Cisplatin, or Docetaxel, or Cisplatin and Helical Tomotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Single-Center Pha2022Technology in cancer research & treatmentRCTFree full text
  8. Comparison of the pre-treatment functional MRI metrics' efficacy in predicting Locoregionally advanced nasopharyngeal carcinoma response to induction chemotherapy.2021Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
All its trials on ClinicalTrials.gov, any status2
  1. Different Chemotherapy Protocols Combined With Intensity Modulated Radiation Therapy in Patients With Locally Advanced Nasopharyngeal CarcinomaCompletedNCT03177174Lead (inferred)N/AStart 2017-06
  2. Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810Status unknownNCT03260179Study sitePhase 1Start 2017-08
More papers found outside PubMed (not counted)14
  1. Efficacy of Helical Tomography (HT) with Concurrent Chemoradiotherapy (CCRT) +Epidermal growth factor receptor (EGFR) inhibitor in Locally advanced nasopharyngeal carcinoma (LANC) patients invading carotid artery and risk of fatal bleeding2024Venue not listedpreprint
  2. Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma2022Figsharedataset
  3. Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  4. Additional file 2 of CapG promoted nasopharyngeal carcinoma cell motility involving Rho motility pathway independent of ROCK2022Figsharedataset
  5. Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  6. Additional file 3 of CapG promoted nasopharyngeal carcinoma cell motility involving Rho motility pathway independent of ROCK2022Figsharedataset
  7. Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  8. Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  9. Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  10. Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  11. Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  12. Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  13. Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  14. Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase2021Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 27 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
27
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 5520212022: 5520222023: 111120232024: 3320242025: 222025

13 hospitals in Beijing for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
    Phase
    Phase 3
    Started
    2021-01
    Registry
    NCT04415853

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesMolecular markers & genomicsImmunotherapyEarly detection & endoscopy
Departments in papersGastroenterology / hepatologyMedical oncologyRadiation oncologyENT / head & neck surgery
Papers it led27
  1. The Clinical Value of hsa_circ_0000419 in Diagnosis and Prognosis of Esophageal Squamous Cell Carcinoma.2026Biochemical genetics
  2. First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306.2025Advances in therapyFree full text
  3. Defect of MLH1 expression sensitized esophageal squamous cell carcinoma cells to Polθ inhibitor.2025EpigenomicsFree full text
  4. Indole-3-Carbinol Promotes Apoptosis and Inhibits the Metastasis of Esophageal Squamous Cell Carcinoma by Downregulating the Wnt/β-Catenin Signaling Pathway.2024Nutrition and cancer
  5. Spatial proteomic profiling elucidates immune determinants of neoadjuvant chemo-immunotherapy in esophageal squamous cell carcinoma.2024Oncogene
  6. TESC acts as a prognostic factor and promotes epithelial-mesenchymal transition progression in esophageal squamous carcinoma.2024Pathology, research and practice
  7. Tumor associated macrophages in esophageal squamous carcinoma: Promising therapeutic implications.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  8. Prognostic value of esophageal cancer immune prognostic index in advanced esophageal squamous cell carcinoma patients with anti-programmed cell death-1 therapy.2023Cancer medicineFree full text
  9. JNK2 Promotes Progression of Esophageal Squamous Cell Carcinoma via Inhibiting Axin2.2023Current pharmaceutical design
  10. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial.2023EBioMedicineFree full text
  11. Early esophageal squamous cell carcinoma and diverticulum were cured simultaneously by endoscopic submucosal dissection in a patient.2023EndoscopyFree full text
  12. RASSF1A promotes ATM signaling and RASSF1A methylation is a synthetic lethal marker for ATR inhibitors.2023Epigenomics
  13. Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway.2023Journal of experimental & clinical cancer research : CRFree full text
  14. FAM107A as a tumor suppressor in esophageal squamous carcinoma inhibits growth and metastasis.2023Pathology, research and practice
  15. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.2023The Lancet. OncologyRCT
  16. Long-term efficacy and predictors of pembrolizumab-based regimens in patients with advanced esophageal cancer in the real world.2023World journal of gastroenterologyFree full text
  17. Linked color imaging vs Lugol chromoendoscopy for esophageal squamous cell cancer and precancerous lesion screening: A noninferiority study.2023World journal of gastroenterologyFree full text
  18. Outcomes of super minimally invasive surgery vs. esophagectomy for superficial esophageal squamous cell carcinoma: a single-center study based on propensity score matching.2022Chinese medical journalFree full text
  19. Paired box 5 increases the chemosensitivity of esophageal squamous cell cancer cells by promoting p53 signaling activity.2022Chinese medical journalFree full text
  20. Efficacy and safety of chemotherapy regimens for first-line treatment of advanced esophageal squamous cell carcinoma in Asia: a systematic review.2022Expert review of anticancer therapy
  21. Melatonin inhibits ESCC tumor growth by mitigating the HDAC7/β-catenin/c-Myc positive feedback loop and suppressing the USP10-maintained HDAC7 protein stability.2022Military Medical ResearchFree full text
  22. Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2).2022Nature communicationsRCTFree full text
  23. Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study.2021BMC gastroenterologyFree full text
  24. Endoscopic resections for superficial esophageal squamous cell epithelial neoplasia: focus on histological discrepancies between biopsy and resected specimens.2021BMC gastroenterologyFree full text
  25. ACP-5862 suppresses esophageal squamous cell carcinoma growth through inducing apoptosis via activation of endoplasmic reticulum stress and ROS production.2021Biochemical and biophysical research communications
  26. Methylation of NRN1 is a novel synthetic lethal marker of PI3K-Akt-mTOR and ATR inhibitors in esophageal cancer.2021Cancer scienceFree full text
  27. Utility of radial incision and cutting with steroid injection for refractory stricture after endoscopic submucosal dissection for large superficial esophageal squamous cell carcinoma.2021Surgical endoscopy
All its trials on ClinicalTrials.gov, any status10
  1. Study of Larotinib in Unresectable Advanced or Recurrent Esophageal CancerRecruitingNCT04415853Study sitePhase 3Start 2021-01
  2. Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal CancerActive, not recruitingNCT06247956Study sitePhase 2Start 2024-03
  3. A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid TumorsTerminatedNCT05427396Study sitePhase 1Start 2022-07
  4. KN046 in Subjects With Late Stage Esophageal Squamous Cell CarcinomaCompletedNCT03925870Study sitePhase 2Start 2019-06
  5. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03783442Study sitePhase 3Start 2018-12
  6. BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction CarcinomaCompletedNCT03469557Study sitePhase 2Start 2017-07
  7. Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene AmplificationCompletedNCT03888092Study sitePhase 1/Phase 2Start 2017-08
  8. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension StudyCompletedNCT03933449Study sitePhase 3Start 2016-12
  9. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT02611700Study sitePhase 3Start 2015-11
  10. Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous CarcinomaStatus unknownNCT01752205Study sitePhase 3Start 2012-11
More papers found outside PubMed (not counted)34
  1. 389MO Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in patients (pts) with locally advanced (LA) esophageal squamous cell carcinoma (ESCC): RATIONALE-306 subgroup analysis2025Annals of Oncologyarticle
  2. Impact of tislelizumab + chemotherapy versus placebo + chemotherapy on patient-reported symptoms and overall survival (OS) by programmed death-ligand 1 (PD-L1) expression in advanced or metastatic esophageal squamous cell carcinoma (ESCC): 2025Journal of Clinical Oncologyconference-abstract
  3. Low-dose chemotherapy and pembrolizumab combined with radiotherapy in the first-line treatment of cT4b esophageal squamous cell carcinoma: A single-arm phase II study.2025Journal of Clinical Oncologyarticle
  4. Nimotuzumab combined with chemotherapy plus immunotherapy as first-line treatment for advanced esophageal squamous cell carcinoma.2025Journal of Clinical Oncologyconference-abstract
  5. Response characteristics of tislelizumab (TIS) plus chemotherapy (chemo) in first-line (1L) treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): A post hoc analysis of RATIONALE-306.2025Journal of Clinical Oncologyconference-abstract
  6. 395MO Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in advanced or metastatic esophageal squamous cell carcinoma (ESCC): PD-L1 biomarker analysis from RATIONALE-3062024Annals of Oncologyarticle
  7. AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC): A single-arm, open-label, multicenter, phase Ib study.2024Journal of Clinical Oncologyconference-abstract
  8. Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow2024Journal of Clinical Oncologyconference-abstract
  9. Nivolumab (NIVO) plus (+) chemotherapy (chemo) or ipilimumab (IPI) vs chemo as 1L treatment for advanced esophageal squamous cell carcinoma (ESCC): First comprehensive biomarker analyses from CheckMate 648.2024Journal of Clinical Oncologyconference-abstract
  10. PCR65 Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality of Life (HRQoL) Outcomes in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC): The Rationale-306 Study2024Value in Healthconference-abstract
  11. 1514P Randomized, global, phase III study of tislelizumab (TIS) + chemotherapy (chemo) vs placebo (PBO) + chemo as first-line (1L) treatment for advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 update2023Annals of Oncologyarticle
  12. A phase 2 study of modified chemotherapy plus pembrolizumab as perioperative therapy for stage II/IIIA esophageal squamous cell carcinoma.2023Journal of Clinical Oncologyconference-abstract
  13. Abstract CT076: Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis2023Cancer Researchconference-abstract
  14. Additional file 1 of Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway2023Figsharedataset
  15. Additional file 1 of Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth2023Figsharedataset
  16. Additional file 2 of FBXW7 loss of function promotes esophageal squamous cell carcinoma progression via elevating MAP4 and ERK phosphorylation2023Figsharedataset
  17. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  18. Additional file 2 of Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth2023Figsharedataset
  19. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  20. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  21. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  22. Randomized, global, phase 3 study of tislelizumab (TIS) + chemotherapy (chemo) versus placebo (PBO) + chemo as first-line (1L) treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Non-Asia subgroup2023Journal of Clinical Oncologyconference-abstract
  23. 196. RISK FACTORS OF CERVICAL LYMPH NODE METASTASIS IN ESCC AND ESTABILISHMENT OF PREDICTION MODEL2022Diseases of the Esophagusarticle
  24. 513. RISK FACTORS OF CERVICAL LYMPH NODE METASTASIS IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA AND ESTABLISHMENT OF RISK PREDICTION MODEL2022Diseases of the Esophagusarticle
  25. 520. EFFICACY AND SAFETY OF NEOADJUVANT CHEMOTHERAPY AND IMMUNOTHERAPY IN LOCALLY RESECTABLE ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA2022Diseases of the Esophagusarticle
  26. 70O Randomized, global, phase III study of tislelizumab (TIS) + chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup2022Annals of Oncologyarticle
  27. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figsharedataset
  28. DNMT3A promotes the proliferation and metastasis of esophageal squamous cell carcinoma via upregulating HDAC92022Research Squarepreprint
  29. RETRACTED ARTICLE: Tumor-associated fibroblasts derived exosomes induce the proliferation and cisplatin resistance in esophageal squamous cell carcinoma cells through RIG-I/IFN-β signaling2022Figsharedataset
  30. Genomic profiling of esophageal squamous cell carcinoma to reveal actionable genetic alterations.2021Journal of Clinical Oncologyconference-abstract
  31. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Squarepreprint
  32. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Squarepreprint
  33. LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling2021Figsharedataset
  34. MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel2021Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 184 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 1.2%.

Papers led
184
2021–2025
Trials led
29
any status, ClinicalTrials.gov
Open trials led
6
recruiting or about to
Open trials as a site
14
led by another institution
Papers led per year
2021: 171720212022: 383820222023: 444420232024: 454520242025: 37372025

17 hospitals in Beijing for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 20

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-06
    Registry
    NCT07018518

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  2. Recruiting
    Image Driven Hepatocellular Carcinoma Invasiveness Evaluation Research
    Phase
    Not given
    Started
    2023-01
    Registry
    NCT06559761

    Age 18 years to 80 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  3. Recruiting
    To Compare the Efficacy of Microwave Ablation and Laparoscopic Hepatectomy for Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2019-12
    Registry
    NCT04365751

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  4. Recruiting
    Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma
    Phase
    Phase 2/Phase 3
    Started
    2009-12
    Registry
    NCT02851784

    Age not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  5. Not yet recruiting
    Fusing Ultrasound and Magnetic Resonance Imaging to Intelligently Plan Highly Conformal Ablation Thermal Field for Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2025-01
    Registry
    NCT06798194

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  6. Not yet recruiting
    CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Registry
    NCT06641453

    Age 18 years to 70 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  7. Recruiting
    A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
    Phase
    Phase 1/Phase 2
    Started
    2026-05
    Registry
    NCT07547553

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin

  8. Recruiting
    TACE Combined Surgery for the Resectable Huge HCC
    Phase
    Not given
    Started
    2025-01
    Registry
    NCT06898398

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  9. Recruiting
    GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07209813

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Nanchang, Nanjing, Zhengzhou

  10. Recruiting
    NWRD06 DNA Plasmid for HCC After Curative Resection.
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07324304

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Harbin

  11. Recruiting
    Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2024-08
    Registry
    NCT06550921

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  12. Recruiting
    The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2024-10
    Registry
    NCT06609850

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  13. Recruiting
    dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2024-10
    Registry
    NCT06609863

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  14. Recruiting
    Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
    Phase
    N/A
    Started
    2024-10
    Registry
    NCT06609876

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  15. Recruiting
    TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT
    Phase
    N/A
    Started
    2024-10
    Registry
    NCT06622031

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  16. Recruiting
    HAIC Compared With TACE in Huge Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2024-10
    Registry
    NCT06641713

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  17. Recruiting
    Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2024-10
    Registry
    NCT06644430

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  18. Recruiting
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Registry
    NCT05024214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Tianjin, Zhengzhou, Zhuhai

  19. Recruiting
    HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2021-01
    Registry
    NCT06333561

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  20. Recruiting
    The Overall Survival of Patients With Unresectable HCC in Real-life
    Phase
    Not given
    Started
    2018-07
    Registry
    NCT03612726

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsLocal treatment (ablation, TACE, HAIC)
Departments in papersRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyMedical oncology
Papers it led184
  1. Low-level viremia increases the risk of adverse long-term outcomes in entecavir-treated patients with chronic hepatitis B.2026Antiviral research
  2. Prognostic Value of Fibrosis-4 in Male Patients with Alcohol-Related Hepatocellular Carcinoma: Implications for Ultrasound-Based Therapeutic Strategies.2026Cancer biotherapy & radiopharmaceuticals
  3. Ultrasound-guided percutaneous ablation outcomes in patients with HBcAb positivity non-B non-C hepatocellular carcinoma: a multicenter long-term follow-up study.2026International journal of surgery (London, England)
  4. Rapid Detection and Purification of Extracellular Vesicles for Hepatocellular Carcinoma Screening Using a Plasmonic Metasurface Integrated with the Kolmogorov-Arnold Network.2025ACS nano
  5. Non-radiomics imaging (US-CEUS) features and clinical text features: correlation with microvascular invasion and tumor grading in hepatocellular carcinoma.2025Abdominal radiology (New York)
  6. The influence of peritumoral parenchyma on local tumor progression of hepatocellular carcinoma after thermal ablation: a retrospective multicenter study.2025Abdominal radiology (New York)
  7. NQO1/p65/CXCL12 Axis-Recruited Tregs Mediate Resistance to Anti-PD-1 Plus Lenvatinib Therapy in PIVKA-II-Positive Hepatocellular Carcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  8. Multi-omics analysis reveals the role of tumor-infiltrating CD4+CCR7+ T cells in EGFR antibody resistance and prognosis of hepatocellular carcinoma.2025BMC cancerFree full text
  9. High frame rate contrast-enhanced ultrasound in hepatocellular carcinoma: biological characteristics and patient outcomes.2025BMC cancerFree full text
  10. Deep learning based on intratumoral heterogeneity predicts histopathologic grade of hepatocellular carcinoma.2025BMC cancerFree full text
  11. Pan-cancer analysis shows that TNFSF4 is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including liver cancer.2025BMC cancerFree full text
  12. Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition).2025Bioscience trends
  13. Conversion therapy followed by surgery and adjuvant therapy improves survival in Barcelona C stage hepatocellular carcinoma - A propensity score-matched analysis.2025Bioscience trends
  14. Cadonilimab, a PD-1/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study.2025Cancer immunology, immunotherapy : CIIFree full text
  15. Correlation Between Treatment-Related Adverse Events and Efficacy of Camrelizumab in Combination With Apatinib in Patients With Unresectable Hepatocellular Carcinoma.2025Cancer medicineFree full text
  16. SLC25A39 identified as a key regulator of hepatocellular carcinoma progression through the mitochondrial ROS-cytochrome c-caspase signaling axis.2025Cellular & molecular biology lettersFree full text
  17. HAND2-AS1 Promotes Ferroptosis to Reverse Lenvatinib Resistance in Hepatocellular Carcinoma by TLR4/NOX2/DUOX2 Axis.2025Current cancer drug targets
  18. Total bile acid is a useful tool for evaluating the risk of portal hypertension in patients with hepatocellular carcinoma who have undergone hepatectomy.2025Current medical research and opinion
  19. Risk factors of complications after thermal ablation for hepatocellular carcinoma: the role of assessment of liver background.2025European journal of gastroenterology & hepatologyFree full text
  20. The impact of cathepsins on liver hepatocellular carcinoma: Insights from genetic and functional analyses.2025Gene
  21. Phosphoproteomics delineates hepatocellular carcinoma subtypes and pinpoints therapeutic targets.2025Hepatology (Baltimore, Md.)
  22. Zinc finger protein 169 promotes tumor progress of hepatocellular cancer via up-regulating cyclin-dependent kinase 19.2025IUBMB life
  23. Risk factors for extrahepatic metastasis after microwave ablation of hepatocellular carcinoma.2025International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  24. Clinical features and risk factors for pelvic metastasis after microwave ablation of hepatocellular carcinoma: a nested case-control study.2025International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  25. Radioresistance in Hepatocellular Carcinoma: Biological Bases and Therapeutic Implications.2025International journal of molecular sciencesFree full text
  26. Relationship between postablation fever and prognosis in initial hepatocellular carcinoma: a 15-year multicenter, retrospective cohort study.2025International journal of surgery (London, England)Free full text
  27. Contrast-enhanced ultrasound-based AI model for multi-classification of focal liver lesions.2025Journal of hepatology
  28. Integration of single-cell and spatial transcriptomics reveals fibroblast subtypes in hepatocellular carcinoma: spatial distribution, differentiation trajectories, and therapeutic potential.2025Journal of translational medicineFree full text
  29. Metastasis-directed ablation of hepatocellular carcinoma with pulmonary oligometastases: a long-term multicenter study.2025La Radiologia medica
  30. Hepatic arterial infusion chemotherapy combined with lenvatinib and immune checkpoint inhibitor versus lenvatinib for advanced hepatocellular carcinoma: a multicenter study with propensity score and coarsened exact matching.2025La Radiologia medicaFree full text
  31. Psoralidin induces pyroptosis in both tumor cells and macrophages as well as enhances nature killer cell cytotoxicity to suppress hepatocellular carcinoma.2025Molecular immunology
  32. Hypericin impedes M2 macrophage polarization and protects against Hepatocellular carcinoma.2025Molecular immunology
  33. Contrast-enhanced US Evaluation of Residual Hepatocellular Carcinoma Following Lenvatinib Combined with Anti-PD-1 Antibody Downstaging Therapy.2025Radiology
  34. Prediction of Macrotrabecular-Massive Hepatocellular Carcinoma and Associated Prognosis Using Contrast-enhanced US and Clinical Features.2025Radiology. Imaging cancerFree full text
  35. HBV reactivation and prognosis after systemic therapy in HCC with undetectable HBV DNA: a multicenter retrospective study.2025Scientific reportsFree full text
  36. Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial.2025Signal transduction and targeted therapyRCTFree full text
  37. An easily machine learning-based tool for preliminary risk assessment of microvascular invasion in hepatocellular carcinoma.2025Surgical endoscopy
  38. Circulating Immune Features Synergizing Neutrophil-to-Lymphocyte Ratio in Prediction of Poor Survival of Early-Stage Hepatocellular Carcinoma After Thermal Ablation.2025Technology in cancer research & treatmentFree full text
  39. Multiparametric magnetic resonance imaging of deep learning-based super-resolution reconstruction for predicting histopathologic grade in hepatocellular carcinoma.2025World journal of gastroenterologyFree full text
  40. Two treatment methods for hepatocellular carcinoma: Lenvatinib or bevacizumab combined with sintilimab and interventional therapy.2025World journal of gastroenterologyFree full text
  41. Targeted redox-responsive peptide for arterial chemoembolization therapy of orthotropic hepatocellular carcinoma.2024Abdominal radiology (New York)Free full text
  42. A combined model based on radiomics features of Sonazoid contrast-enhanced ultrasound in the Kupffer phase for the diagnosis of well-differentiated hepatocellular carcinoma and atypical focal liver lesions: a prospective, multicenter study.2024Abdominal radiology (New York)
  43. The diagnositic value of dynamic contrast-enhanced ultrasound for evaluation of tissue oxygen status in rat hepatoma model.2024BMC gastroenterologyFree full text
  44. Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study.2024Cancer immunology, immunotherapy : CIIFree full text
  45. CCL5/CCR5/CYP1A1 pathway prompts liver cancer cells to survive in the combination of targeted and immunological therapies.2024Cancer scienceFree full text
  46. Five miRNAs identified in fucosylated extracellular vesicles as non-invasive diagnostic signatures for hepatocellular carcinoma.2024Cell reports. MedicineFree full text
  47. No Incidence of Liver Cancer Was Observed in A Retrospective Study of Patients with Aristolochic Acid Nephropathy.2024Chinese journal of integrative medicine
  48. Total bile acid as a preoperative risk factor for post-hepatectomy liver failure in patients with hepatocellular carcinoma and normal bilirubin.2024Cirugia espanola
  49. Age-Dependent Female Survival Advantage in Hepatocellular Carcinoma: A Multicenter Cohort Study.2024Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  50. Epigenetic silencing of KCTD8 promotes hepatocellular carcinoma growth by activating PI3K/AKT signaling.2024EpigenomicsFree full text
  51. Feeding artery: a valuable feature for differentiation of regenerative nodule, dysplastic nodules and small hepatocellular carcinoma in CEUS LI-RADS.2024European radiology
  52. Focal liver lesions: multiparametric microvasculature characterization via super-resolution ultrasound imaging.2024European radiology experimentalFree full text
  53. Hyaluronic acid-modified extracellular vesicles for targeted doxorubicin delivery in hepatocellular carcinoma.2024Experimental cell research
  54. Prognostic significance of early alpha fetoprotein and des-gamma carboxy prothrombin responses in unresectable hepatocellular carcinoma patients undergoing triple combination therapy.2024Frontiers in immunologyFree full text
  55. The utility of P-I-R classification in predicting the on-treatment histological and clinical outcomes of patients with hepatitis B and advanced liver fibrosis.2024Hepatology (Baltimore, Md.)RCTFree full text
  56. Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C Infection: a systematic review and meta-analysis.2024Hepatology international
  57. Efficacy and safety of robotic versus laparoscopic liver resection for hepatocellular carcinoma: a propensity score-matched retrospective cohort study.2024Hepatology internationalFree full text
  58. A Recombinant Oncolytic Influenza Virus Carrying GV1001 Triggers an Antitumor Immune Response.2024Human gene therapy
  59. Combination Immunotherapy of Oncolytic Flu-Vectored Virus and Programmed Cell Death 1 Blockade Enhances Antitumor Activity in Hepatocellular Carcinoma.2024Human gene therapy
  60. Integration of single-cell sequencing and drug sensitivity profiling reveals an 11-gene prognostic model for liver cancer.2024Human genomicsFree full text
  61. Enhanced NK cell activation via eEF2K-mediated potentiation of the cGAS-STING pathway in hepatocellular carcinoma.2024International immunopharmacology
  62. Ultrasound-guided percutaneous microwave ablation for metabolic-associated fatty liver disease-related hepatocellular carcinoma (HCC) versus hepatitis virus B-related HCC: a propensity score matching study.2024International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  63. Stereotactic Body Radiotherapy Combined With Lenvatinib With or Without PD-1 Inhibitors as Initial Treatment for Unresectable Hepatocellular Carcinoma.2024International journal of radiation oncology, biology, physics
  64. Transarterial chemoembolization combined with sintilimab and lenvatinib for the treatment of unresectable hepatocellular carcinoma: a retrospective study.2024Journal of cancer research and clinical oncologyFree full text
  65. Effect of stability of PTEN on hepatocellular carcinoma.2024Journal of cancer research and therapeutics
  66. Liuweiwuling Tablet relieves the inflammatory transformation of hepatocellular carcinoma by inhibiting the PI3K/AKT/NF-κB signaling pathway.2024Journal of ethnopharmacology
  67. Three-dimensional chromatin landscapes in hepatocellular carcinoma associated with hepatitis B virus.2024Journal of gastroenterology
  68. Causal relationship between gout and liver cancer: A Mendelian randomization and transcriptome analysis.2024MedicineFree full text
  69. A natural killer T cell nanoagonist-initiated immune cascade for hepatocellular carcinoma synergistic immunotherapy.2024Nanoscale
  70. Degradation of FAK-targeting by proteolytic targeting chimera technology to inhibit the metastasis of hepatocellular carcinoma.2024Oncology researchFree full text
  71. Differentiating HCC from ICC and prediction of ICC grade based on MRI deep-radiomics: Using lesions and their extended regions.2024Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)
  72. MRI non-rigid registration with tumor contraction correction for ablative margin assessment after microwave ablation of hepatocellular carcinomas.2024Physics in medicine and biology
  73. Human diet-derived polyphenolic compounds and hepatic diseases: From therapeutic mechanisms to clinical utilization.2024Phytotherapy research : PTR
  74. Stereotactic body radiotherapy versus lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity matching score analysis.2024Radiation oncology (London, England)Free full text
  75. Safety of local thermal ablation in hepatocellular carcinoma patients with cirrhosis and severe thrombocytopenia.2024Scientific reportsFree full text
  76. Transcatheter arterial chemoembolization plus Sorafenib versus transcatheter arterial chemoembolization plus Lenvatinib for intermediate hepatocellular carcinoma.2024Scientific reportsFree full text
  77. Perioperative impact of liver cirrhosis on robotic liver resection for hepatocellular carcinoma: a retrospective cohort study.2024Surgical endoscopy
  78. Dendritic cell-cytokine killer combined with microwave ablation reduced recurrence for hepatocellular carcinoma compared to ablation alone.2024Technology and health care : official journal of the European Society for Engineering and Medicine
  79. Prediction Model for Immunotherapy Efficacy in Hepatocellular Carcinoma Based on Alternative Splicing Sequencing Data.2024Technology in cancer research & treatmentFree full text
  80. Efficacy of Lenvatinib in Combination With PD-1 Monoclonal Antibody and Interventional Treatment for Intermediate-Stage Hepatocellular Carcinoma: Impact on Serum Vascular Endothelial Growth Factor and Matrix Metalloproteinase-9 Levels: A Re2024Technology in cancer research & treatmentFree full text
  81. Feasibility and safety of robotic liver resection for huge (≥10 cm) hepatocellular carcinoma in a single centre: A propensity score-matched single-surgeon study.2024The international journal of medical robotics + computer assisted surgery : MRCAS
  82. More Ultrasound-Guided Percutaneous Microwave Ablation Leads to Higher Immune-Related Gene Expression and Boosts PD-1 Monoclonal Antibodies for Liver Cancer.2024Ultrasound in medicine & biology
  83. N6-methyladenosine-modified long non-coding RNA KIF9-AS1 promotes stemness and sorafenib resistance in hepatocellular carcinoma by upregulating SHOX2 expression.2024World journal of gastroenterologyFree full text
  84. Review on article of preoperative prediction in chronic hepatitis B virus patients using spectral computed tomography and machine learning.2024World journal of gastroenterologyFree full text
  85. Development of a nomogram for predicting liver transplantation prognosis in hepatocellular carcinoma.2024World journal of gastroenterologyFree full text
  86. Nomogram based on Sonazoid contrast-enhanced ultrasound to differentiate intrahepatic cholangiocarcinoma and poorly differentiated hepatocellular carcinoma: a prospective multicenter study.2023Abdominal radiology (New York)
  87. Predictive value of prognostic nutritional index (PNI) in recurrent or unresectable hepatocellular carcinoma received anti-PD1 therapy.2023BMC cancerFree full text
  88. Nomogram for predicting survival in patients with advanced hepatocellular carcinoma treated with PD-1 inhibitors: incorporating pre-treatment and post-treatment clinical parameters.2023BMC cancerFree full text
  89. Long-term survival and portal vein patency with novel PVTT surgery approach in advanced HCC patients with Vp3/4 PVTT following combination therapy of TKIs and PD-1 inhibitors.2023BMC surgeryFree full text
  90. Short-term outcomes of robotic versus open hepatectomy among overweight patients with hepatocellular carcinoma: a propensity score-matched study.2023BMC surgeryFree full text
  91. Comparison of machine learning models and CEUS LI-RADS in differentiation of hepatic carcinoma and liver metastases in patients at risk of both hepatitis and extrahepatic malignancy.2023Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  92. Radiofrequency ablation combined with toripalimab for recurrent hepatocellular carcinoma: A prospective controlled trial.2023Cancer medicineFree full text
  93. TPX2 enhances the transcription factor activation of PXR and enhances the resistance of hepatocellular carcinoma cells to antitumor drugs.2023Cell death & diseaseFree full text
  94. Effectiveness of lenvatinib plus immune checkpoint inhibitors in primary advanced hepatocellular carcinoma beyond oligometastasis.2023Clinical and translational medicineFree full text
  95. Study on anxiety and depression in elderly patients with malignant liver tumor undergoing hepatectomy.2023European journal of medical researchFree full text
  96. Learning curve of microwave ablation for liver cancers.2023European journal of radiology
  97. The tumor ghost on MRI after microwave ablation for hepatocellular carcinoma: A new modality to assess the ablative margin.2023European journal of radiology
  98. Ring-like enhancement on Contrast-Enhanced ultrasound may correlate well with histopathological capsule of Hepatocellular Carcinoma: Comparison with the enhancing capsule on Gadopentetate-enhanced MRI.2023European journal of radiology
  99. Analysis of Sonazoid contrast-enhanced ultrasound for predicting the risk of microvascular invasion in hepatocellular carcinoma: a prospective multicenter study.2023European radiology
  100. A pan-cancer analysis of the prognostic implication and oncogenic role of tubulin epsilon and delta complex 2 (TEDC2) in human tumors.2023Frontiers in immunologyFree full text
  101. Comprehensive analysis and immune landscape of chemokines- and chemokine receptors-based signature in hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  102. Estrogen-related genes influence immune cell infiltration and immunotherapy response in Hepatocellular Carcinoma.2023Frontiers in immunologyFree full text
  103. Comparison of survival benefit between salvage surgery after conversion therapy versus surgery alone for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis.2023HPB : the official journal of the International Hepato Pancreato Biliary Association
  104. Combined hepatic segment color rendering technique improves the outcome of anatomical hepatectomy in patients with hepatocellular carcinoma.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  105. Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors.2023Hepatology international
  106. Whole-exome sequencing identifies a set of genes as markers of hepatocellular carcinoma early recurrence.2023Hepatology international
  107. A recombinant oncolytic influenza virus expressing a PD-L1 antibody induces CD8+ T-cell activation via the cGas-STING pathway in mice with hepatocellular carcinoma.2023International immunopharmacology
  108. Intratumoral perfusion may affect microwave ablation area of hepatocellular carcinoma.2023International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  109. Long-term efficacy and safety of microwave ablation for hepatocellular carcinoma adjacent to the gallbladder with a diameter ≤ 5 cm: a multicenter, propensity score matching study.2023International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  110. Peripheral immune factors aiding clinical parameter for better early recurrence prediction of hepatocellular carcinoma after thermal ablation.2023International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia GroupRCT
  111. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.2023Journal for immunotherapy of cancerFree full text
  112. MicroRNA-155 downregulates long noncoding RNA prostate cancer-associated transcript 29 in hepatocellular carcinoma to suppress cancer cell invasion and migration.2023Journal of biochemical and molecular toxicologyFree full text
  113. Comparison of stereotactic body radiotherapy with and without lenvatinib for advanced hepatocellular carcinoma: a propensity score analysis.2023Journal of cancer research and clinical oncologyFree full text
  114. Prognostic and pathological implications of contrast-enhanced ultrasound features in hepatocellular carcinoma.2023Journal of cancer research and therapeutics
  115. Prediction of local tumor progression after microwave ablation for early-stage hepatocellular carcinoma with machine learning.2023Journal of cancer research and therapeutics
  116. High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy.2023Journal of gastroenterologyRCT
  117. Reply to: "Biejia-Ruangan compound and incidence of hepatocellular carcinoma".2023Journal of hepatology
  118. On-Site Diagnostic Ability of CEUS/CT/MRI for Hepatocellular Carcinoma (2019-2022): A Multicenter Study.2023Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  119. Efficacy and safety of HAIC alone vs. HAIC combined with lenvatinib for treatment of advanced hepatocellular carcinoma.2023Medical oncology (Northwood, London, England)
  120. Propofol Inhibits Biological Function of Hepatocellular Carcinoma Cells through LINC00475-Mediated Sonic Hedgehog Pathway.2023Pharmacology
  121. Prostate arterial chemoembolization for treatment of refractory hematuria and urinary retention in patients with localized advanced prostate cancer.2023Prostate cancer and prostatic diseases
  122. Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective study.2023Radiation oncology (London, England)Free full text
  123. Lymphocyte subsets and inflammatory factors as predictors of immunotherapy efficacy in patients with hepatocellular carcinoma.2023Scientific reportsFree full text
  124. Cellular senescence affects energy metabolism, immune infiltration and immunotherapeutic response in hepatocellular carcinoma.2023Scientific reportsFree full text
  125. Long Noncoding RNAs in the Prediction of Survival of Patients with Digestive Cancers.2023The Turkish journal of gastroenterology : the official journal of Turkish Society of GastroenterologyFree full text
  126. Platelet membrane-derived microparticles may be biomarkers in patients with hepatocellular carcinoma and can promote the invasion and metastasis of hepatoma carcinoma cells.2023Transfusion
  127. A Nomogram Based on Contrast-Enhanced Ultrasound to Predict the Microvascular Invasion in Hepatocellular Carcinoma.2023Ultrasound in medicine & biology
  128. Clinicopathological features and differential diagnosis of gastric metastases.2023World journal of surgical oncologyFree full text
  129. Efficacy of treatment based on TKIs in combination with PD-1 inhibitors for unresectable recurrent hepatocellular carcinoma.2023World journal of surgical oncologyFree full text
  130. Preoperative serum hepatitis B virus DNA was a risk factor for hepatocellular carcinoma recurrence after liver transplantation.2022Annals of medicineFree full text
  131. Laparoscopic hepatectomy versus open hepatectomy for tumors located in right posterior segment: A single institution study.2022Asian journal of surgery
  132. Sorafenib inhibits interferon production by plasmacytoid dendritic cells in hepatocellular carcinoma.2022BMC cancerFree full text
  133. Stereotactic body radiation therapy as an effective local treatment for advanced hepatocellular carcinoma patients with inferior vena cava and right atrial tumor thrombus.2022BMC gastroenterologyFree full text
  134. Long intergenic non-protein coding RNA 1273 confers sorafenib resistance in hepatocellular carcinoma via regulation of methyltransferase 3.2022BioengineeredFree full text
  135. Overexpression of Protein Phosphatase 2 Regulatory Subunit B"Alpha Promotes Glycolysis by Regulating Hexokinase 1 in Hepatocellular Carcinoma.2022Biomedical and environmental sciences : BES
  136. MBD3 promotes hepatocellular carcinoma progression and metastasis through negative regulation of tumour suppressor TFPI2.2022British journal of cancerFree full text
  137. The advanced development of molecular targeted therapy for hepatocellular carcinoma.2022Cancer biology & medicineFree full text
  138. Multiparametric liver MRI for predicting early recurrence of hepatocellular carcinoma after microwave ablation.2022Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  139. Treatment of unresectable intrahepatic cholangiocarcinoma using transarterial chemoembolisation with irinotecan-eluting beads: analysis of efficacy and safety.2022Cardiovascular and interventional radiology
  140. bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti-angiogenic agent apatinib combination therapy.2022Clinical and translational medicineFree full text
  141. Percutaneous microwave ablation versus robot-assisted hepatectomy for early hepatocellular carcinoma: A real-world single-center study.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  142. Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study.2022Drug design, development and therapyFree full text
  143. Perioperative factors related to the prognosis of elderly patients with hepatocellular carcinoma.2022European journal of medical researchFree full text
  144. Are all local tumour progressions of HCC related to thermal ablation? A study of the causes and classification of local tumour progression.2022European radiology
  145. Prognosis and Tumour Immune Microenvironment of Patients With Hepatocellular Carcinoma by a Novel Pyroptosis-Related lncRNA Signature.2022Frontiers in immunologyFree full text
  146. Construction and validation of a novel signature based on epithelial-mesenchymal transition-related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment.2022Functional & integrative genomicsFree full text
  147. Prediction of early recurrence of hepatocellular carcinoma after liver transplantation based on computed tomography radiomics nomogram.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  148. Microwave ablation versus laparoscopic resection as first-line therapy for solitary 3-5-cm HCC.2022Hepatology (Baltimore, Md.)
  149. Immunological alterations after immunotherapy with short lived HBV-TCR T cells associates with long-term treatment response in HBV-HCC.2022Hepatology communicationsFree full text
  150. Prevention of variceal rebleeding in cirrhotic patients with advanced hepatocellular carcinoma receiving molecularly targeted therapy: a randomized pilot study of transjugular intrahepatic portosystemic shunt versus endoscopic plus β-blocke2022Hepatology internationalRCT
  151. Therapeutic Efficacy of an Oncolytic Influenza Virus Carrying an Antibody Against Programmed Cell Death 1 in Hepatocellular Carcinoma.2022Human gene therapy
  152. Robotic laser position versus freehand in CT-guided percutaneous microwave ablation for single hepatocellular carcinoma (diameter < 3 cm): a preliminary study.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  153. Radiomics analysis of ultrasound to predict recurrence of hepatocellular carcinoma after microwave ablation.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia GroupRCT
  154. Long-term efficacy of microwave ablation in the treatment of subcapsular hepatocellular carcinomas of ≤3 cm in diameter: a multicenter, propensity score-matched study.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  155. Comparison of percutaneous microwave ablation and surgical resection for hepatocellular carcinoma in the caudate lobe.2022Journal of cancer research and therapeutics
  156. Comprehensive Analysis of Epigenetic Associated Genes on Differential Gene Expression and Prognosis in Hepatocellular Carcinoma.2022Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  157. Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis.2022Journal of gastroenterologyFree full text
  158. Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B.2022Journal of hepatologyRCT
  159. MicroRNA-149 rs2292832 C/T Polymorphism Predicts the Prognosis of Hepatocellular Carcinoma Patients With Bone Metastasis.2022Laboratory medicine
  160. Efficacy and safety of percutaneous cryoablation for elderly patients with small hepatocellular carcinoma: A prospective multicenter study.2022Liver international : official journal of the International Association for the Study of the Liver
  161. Dynamic changes in liver volume calculated using a three-dimensional visualisation system after microwave ablation of hepatocellular carcinomas.2022Medical physics
  162. Prognostic significance of long noncoding RNA HOTAIR in hepatocellular carcinoma: A protocol for systematic review and meta-analysis.2022MedicineFree full text
  163. ISOC1 is a novel potential tumor suppressor in hepatocellular carcinoma.2022Neoplasma
  164. Identification of a new five-gene risk score for risk stratification and prognosis prediction in HCC.2022Nucleosides, nucleotides & nucleic acids
  165. Proteome expression profiling of red blood cells during the tumorigenesis of hepatocellular carcinoma.2022PloS oneFree full text
  166. Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis.2022Technology in cancer research & treatmentFree full text
  167. Effect of perioperative factors on the prognosis of patients with hepatocellular carcinoma who underwent hepatectomy.2022Turkish journal of medical sciencesFree full text
  168. Mannose-Derived Carbon Dots Amplify Microwave Ablation-Induced Antitumor Immune Responses by Capturing and Transferring "Danger Signals" to Dendritic Cells.2021ACS nano
  169. Robotic anatomic isolated complete caudate lobectomy: Left-side approach and techniques.2021Asian journal of surgery
  170. Intraarterial contrast-enhanced ultrasound to predict the short-term tumour response of hepatocellular carcinoma to Transarterial chemoembolization with Lipiodol.2021BMC cancerFree full text
  171. MARCH6 promotes hepatocellular carcinoma development through up-regulation of ATF2.2021BMC cancerFree full text
  172. Microarray Data Mining and Preliminary Bioinformatics Analysis of Hepatitis D Virus-Associated Hepatocellular Carcinoma.2021BioMed research internationalFree full text
  173. Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial.2021Clinical cancer research : an official journal of the American Association for Cancer Research
  174. The safety and efficacy of transarterial chemoembolisation with bleomycin for hepatocellular carcinoma unresponsive to doxorubicin: a prospective single-centre study.2021Clinical radiologyRCT
  175. Long-term outcomes of individualized interventional treatment for primary Budd-Chiari syndrome complicated by inferior vena cava thrombosis.2021European journal of gastroenterology & hepatology
  176. The effects of stereotactic body radiotherapy on peripheral natural killer and CD3+CD56+ NKT-like cells in patients with hepatocellular carcinoma.2021Hepatobiliary & pancreatic diseases international : HBPD INT
  177. Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial.2021Hepatology internationalFree full text
  178. Percutaneous thermal ablation versus open liver resection for recurrent hepatoblastoma: a retrospective study.2021International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  179. Colonic metastasis from hepatocellular carcinoma after treated by ablation and transarterial chemoembolization manifested by intestinal obstruction: A case report and review of the literature.2021Journal of cancer research and therapeutics
  180. BCL6B hypermethylation predicts metastasis and poor prognosis in early-stage hepatocellular carcinoma after thermal ablation.2021Journal of cancer research and therapeutics
  181. The prognostic values of serum markers in hepatocellular carcinoma after invasive therapies based on real-world data.2021Journal of clinical laboratory analysisFree full text
  182. Percutaneous Argon-Helium Cryoablation for Small Hepatocellular Carcinoma Located Adjacent to a Major Organ or Viscus: A Retrospective Study of 92 Patients at a Single Center.2021Medical science monitor : international medical journal of experimental and clinical researchFree full text
  183. Upregulation of long noncoding RNA W42 promotes tumor development by binding with DBN1 in hepatocellular carcinoma.2021World journal of gastroenterologyFree full text
  184. Long non-coding ribonucleic acid W5 inhibits progression and predicts favorable prognosis in hepatocellular carcinoma.2021World journal of gastroenterologyFree full text
Chinese-language papers (not in the count)12
  1. [Analysis of the impact of tumor diameter on short-term prognosis in patients with hepatitis B-related hepatocellular carcinoma-inducing acute-on-chronic liver failure].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  2. [Application and progress of ablation therapy for large liver cancer].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  3. [Curative effect of percutaneous microwave ablation therapy on hepatocellular carcinoma survival: a 15-year real-world study].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  4. [Spatial distribution pattern of local tumor progression analysis after microwave ablation of hepatocellular carcinoma based on three-dimensional magnetic resonance imaging].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  5. [17-year study on the curative effect of treatment to prevent the recurrence of hepatitis B in different risk groups after liver transplantation].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  6. [A retrospective study of postoperative adjuvant therapy following immunotherapy combined with targeted therapy and sequential curative surgical procedures for initially unresectable hepatocellular carcinoma].2024Zhonghua wai ke za zhi [Chinese journal of surgery]
  7. [Lamin B1 regulates the growth of hepatocellular carcinoma cells by influencing telomerase activity].2023Sheng wu gong cheng xue bao = Chinese journal of biotechnology
  8. [A preliminary discussion on carnosine dipeptidase 1 as a potential novel biomarker for the diagnostic and prognostic evaluation of hepatocellular carcinoma].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  9. [Value of autocrine motility factors in the prediction of the disease progression of PBC- associated hepatocellular carcinoma].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  10. [The companion diagnostics of targeted therapy and immunotherapy for hepatocellular carcinoma].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  11. [The progress and challenges in immunotherapy for the difficulty- to- treat liver diseases].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  12. [Analysis of factors influencing radiation-induced liver injury caused by stereotactic radiotherapy in patients with primary hepatocellular carcinoma].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status67
  1. Fusing Ultrasound and Magnetic Resonance Imaging to Intelligently Plan Highly Conformal Ablation Thermal Field for Hepatocellular CarcinomaNot yet recruitingNCT06798194Lead sponsorStart 2025-01
  2. PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular CarcinomaRecruitingNCT07018518Lead sponsorPhase 1Start 2025-06
  3. CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular CarcinomaNot yet recruitingNCT06641453Lead sponsorPhase 1/Phase 2Start 2024-11
  4. Image Driven Hepatocellular Carcinoma Invasiveness Evaluation ResearchRecruitingNCT06559761Lead sponsorStart 2023-01
  5. To Compare the Efficacy of Microwave Ablation and Laparoscopic Hepatectomy for Hepatocellular CarcinomaRecruitingNCT04365751Lead sponsorN/AStart 2019-12
  6. Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular CarcinomaRecruitingNCT02851784Lead sponsorPhase 2/Phase 3Start 2009-12
  7. Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular CarcinomaStatus unknownNCT06463522Lead sponsorPhase 1/Phase 2Start 2024-07
  8. Microvascular Invasion Artificial Intelligence Prediction Via Contrast-enhanced Ultrasound With ExplainabilityCompletedNCT06760494Lead sponsorStart 2023-11
  9. The Surveillance of Hepatocellular CarcinomaStatus unknownNCT05286099Lead sponsorStart 2022-01
  10. Plan for Microwave Thermal FieldStatus unknownNCT05270642Lead sponsorN/AStart 2021-10
  11. Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCCStatus unknownNCT04665609Lead sponsorPhase 3Start 2021-03
  12. CyberKnife Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma Patients With Decompensated CirrhosisStatus unknownNCT04512833Lead sponsorStart 2020-08
  13. Comparison of Efficacy in SBRT of Large HCC With or Without TACEStatus unknownNCT04512846Lead sponsorStart 2020-08
  14. Allogeneic "Gammadelta T Cells (γδ T Cells)" Cell Immunotherapy in Phase 1 Hepatocellular Carcinoma Clinical TrialStatus unknownNCT04518774Lead sponsorEarly phase 1Start 2020-08
  15. By Developing a Radiomics Model to Predict the Prognosis of Patients With Hepatocellular Carcinoma After Microwave AblationStatus unknownNCT03880721Lead sponsorStart 2019-01
  16. Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular CarcinomaStatus unknownNCT04162158Lead sponsorPhase 1/Phase 2Start 2019-03
  17. Immunotherapy of Advanced Hepatitis B Related Hepatocellular Carcinoma With γδT CellsStatus unknownNCT04032392Lead sponsorPhase 1Start 2019-07
  18. TCR-Redirected T Cells Therapy in Patient With HBV Related HCCStatus unknownNCT03899415Lead sponsorPhase 1Start 2019-04
  19. Comparison of Efficacy in SBRT of HCC ≤5 cm With or Without TACEStatus unknownNCT04161287Lead sponsorStart 2019-10
  20. The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver CancerStatus unknownNCT04204577Lead sponsorPhase 2Start 2019-11
  21. Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical ResectionStatus unknownNCT05213637Lead sponsorPhase 2Start 2018-04
  22. A Study Combining Personalized Neoantigen-based Dendritic Cell Vaccine With Microwave Ablation for the Treatment of Hepatocellular CarcinomaCompletedNCT03674073Lead sponsorPhase 1Start 2018-10
  23. Central Obesity and Hepatocellular CarcinomaStatus unknownNCT03082378Lead sponsorStart 2017-03
  24. Recombinant Human Endostatin(Rh-endostatin) Combine With Radiotherapy in the Treatment of Hepatocellular Carcinoma(HCC)Status unknownNCT03208335Lead sponsorPhase 2Start 2017-01
  25. Targeted and Staged Cyber Knife Combined With Interventional Therapy in the Treatment of MHCCStatus unknownNCT03243916Lead sponsorN/AStart 2017-08
  26. Study of Liver Resection With Versus Without Hepatic Inflow Occlusion for the HBV-related HCCStatus unknownNCT02563158Lead sponsorN/AStart 2016-01
  27. Autologous Natural Killer T Cells Infusion for the Treatment of CancerStatus unknownNCT01801852Lead sponsorN/AStart 2013-01
  28. Comparison of Microwave and Radiofrequency Ablation for LiverCompletedNCT02539212Lead sponsorN/AStart 2008-10
  29. Clinical Decision Biological Biomarker and Prognosis Prediction of Hepatocellular Carcinoma by Deep LearningStatus unknownNCT05257694Lead (inferred)Start 2022-01
  30. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCCRecruitingNCT07547553Study sitePhase 1/Phase 2Start 2026-05
  31. GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07209813Study sitePhase 2Start 2025-11
  32. NWRD06 DNA Plasmid for HCC After Curative Resection.RecruitingNCT07324304Study sitePhase 2Start 2025-12
  33. TACE Combined Surgery for the Resectable Huge HCCRecruitingNCT06898398Study siteStart 2025-01
  34. TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTTRecruitingNCT06622031Study siteN/AStart 2024-10
  35. The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular CarcinomaRecruitingNCT06609850Study siteN/AStart 2024-10
  36. HAIC Compared With TACE in Huge Hepatocellular CarcinomaRecruitingNCT06641713Study siteStart 2024-10
  37. Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCCRecruitingNCT06609876Study siteN/AStart 2024-10
  38. Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular CarcinomaRecruitingNCT06550921Study siteN/AStart 2024-08
  39. Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular CarcinomaRecruitingNCT06644430Study siteStart 2024-10
  40. dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular CarcinomaRecruitingNCT06609863Study siteN/AStart 2024-10
  41. Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsRecruitingNCT05024214Study sitePhase 1/Phase 2Start 2021-11
  42. HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular CarcinomaRecruitingNCT06333561Study siteStart 2021-01
  43. The Overall Survival of Patients With Unresectable HCC in Real-lifeRecruitingNCT03612726Study siteStart 2018-07
  44. Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular CarcinomaStatus unknownNCT06624098Study siteN/AStart 2024-10
  45. Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC PatientsActive, not recruitingNCT05377034Study sitePhase 2Start 2022-10
  46. GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular CarcinomaTerminatedNCT05352542Study sitePhase 1Start 2022-05
  47. KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular CarcinomaTerminatedNCT04601610Study sitePhase 1/Phase 2Start 2021-06
  48. HELIO Liver Test Performance Study in China (HEPATIC)CompletedNCT05053412Study siteStart 2021-09
  49. A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)TerminatedNCT04985136Study sitePhase 3Start 2021-09
  50. MB07133 for the Treatment of Patients With Unresectable Hepatocellular CarcinomaStatus unknownNCT06141096Study sitePhase 2Start 2020-01
  51. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  52. A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular CarcinomaCompletedNCT04444167Study sitePhase 1/Phase 2Start 2020-07
  53. SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular CarcinomaStatus unknownNCT04560894Study sitePhase 2/Phase 3Start 2020-11
  54. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Study sitePhase 3Start 2020-10
  55. Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver TumorsStatus unknownNCT04951141Study siteEarly phase 1Start 2019-01
  56. NeuWave Microwave Ablation HCC China StudyCompletedNCT03783871Study siteN/AStart 2019-02
  57. A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)CompletedNCT04172571Study sitePhase 2Start 2018-11
  58. Study of BGB-A317 in Participants With Previously Treated Unresectable HCCCompletedNCT03419897Study sitePhase 2Start 2018-04
  59. Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local AblationStatus unknownNCT03356236Study siteStart 2018-04
  60. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Study sitePhase 3Start 2017-12
  61. Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810Status unknownNCT03260179Study sitePhase 1Start 2017-08
  62. The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma SubjectsTerminatedNCT03236649Study sitePhase 3Start 2017-09
  63. A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART)Status unknownNCT03130712Study sitePhase 1/Phase 2Start 2017-04
  64. Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)CompletedNCT02112656Study sitePhase 3Start 2014-06
  65. Efficacy and Safety Study of TLC388 to Advanced Hepatocellular CarcinomaTerminatedNCT02267213Study sitePhase 2Start 2014-04
  66. Axitinib For The Treatment Of Advanced Hepatocellular CarcinomaCompletedNCT01210495Study sitePhase 2Start 2010-12
  67. Urea Cream Treatment Sorafenib-Associated HSFR in HCCCompletedNCT01934829Study sitePhase 2Start 2009-07

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 140 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 1.4%.

Papers led
140
2021–2025
Trials led
28
any status, ClinicalTrials.gov
Open trials led
6
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 232320212022: 222220222023: 333320232024: 333320242025: 26262025

15 hospitals in Beijing for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 9

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07212933

    Age 18 years to 70 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  2. Recruiting
    Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07392346

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  3. Recruiting
    Helicobacter Pylori Infection Status and Pathological Features for Predicting Gastric Cancer Biological Behavior and Prognosis: A Real-World Observational Study
    Phase
    Not given
    Started
    2024-01
    Registry
    NCT07724496

    Age 18 years to 80 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  4. Recruiting
    Oxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric Cancer
    Phase
    Phase 3
    Started
    2021-01
    Registry
    NCT04483076

    Age 18 years to 70 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  5. Not yet recruiting
    Prospective Observational Cohort Study
    Phase
    Not given
    Started
    2024-07
    Registry
    NCT06493448

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  6. Enrolling by invitation
    EGPSS for Weight Management in an in Vivo Human Model
    Phase
    N/A
    Started
    2024-07
    Registry
    NCT07186959

    Age 18 years to 70 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  7. Recruiting
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    Phase
    Phase 3
    Started
    2026-12
    Registry
    NCT07789184

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an

  8. Recruiting
    A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients
    Phase
    Phase 3
    Started
    2025-08
    Registry
    NCT07103668

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  9. Recruiting
    KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
    Phase
    Phase 2/Phase 3
    Started
    2022-04
    Registry
    NCT05427383

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEarly detection & endoscopyPeritoneal spread & advanced diseaseSurgery
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyMedical oncologyPathology / laboratory medicine
Papers it led140
  1. Therapeutic efficacy and oncological prognosis of ypTNM 0-I gastric cancer after neoadjuvant therapy: a multicenter propensity-score matched study in China.2026Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  2. Endoscopic full-thickness resection for early gastric cancer: a multicenter retrospective study from the National Early Gastrointestinal Cancer Cohort (NEGCC).2026International journal of surgery (London, England)Free full text
  3. Clinical outcomes of extensive endoscopic submucosal dissection involving more than three-fourths of the circumference for gastric epithelial neoplasia.2026Surgical endoscopy
  4. Dissecting the Spatial and Single-Cell Transcriptomic Architecture of Cancer Stem Cell Niche Driving Tumor Progression in Gastric Cancer.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  5. 177Lu-Dotatate versus high-dose long-acting octreotide for the treatment of patients with advanced, grade 1-2, well-differentiated gastroenteropancreatic neuroendocrine tumours (XT-XTR008-3-01): an open-label, randomised, phase III trial.2025Annals of oncology : official journal of the European Society for Medical OncologyRCT
  6. Is Adjuvant Therapy Necessary for Stage IB Gastric Cancer: A Retrospective Cohort Study.2025Annals of surgical oncologyFree full text
  7. Development and validation of a novel nerve-related prognostic model for gastric cancer based on bulk and single-cell RNA sequencing data.2025BMC cancerFree full text
  8. Linked color imaging for detection and characterization of gastrointestinal neuroendocrine tumors.2025BMC gastroenterologyFree full text
  9. Gastric cancer liver metastases in China: a real-world, multicentre, prospective, observational cohort study protocol.2025BMJ openFree full text
  10. Association of Antibiotic Used During Surgery With the Outcome in Stage I-III Gastric Cancer.2025Cancer control : journal of the Moffitt Cancer CenterFree full text
  11. Exploration of the benefits and resistance mechanisms of immunotherapy based on PD-L1 expression, circulating tumor DNA and T-cell receptor profiles in advanced gastric cancer.2025Cancer immunology, immunotherapy : CIIFree full text
  12. The regulatory and synergistic effects of FBP2 and HKDC1 on glucose metabolism and malignant progression in gastric cancer.2025Cell death & diseaseFree full text
  13. Prognostic value of a novel myeloid-to-lymphoid ratio biomarker in advanced gastric cancer.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of MexicoFree full text
  14. A novel lncRNA, Lnc21q22.11, suppresses gastric cancer growth by inhibiting MEK/ERK pathway.2025EpigeneticsFree full text
  15. TIGD6 in gastric cancer: exploring its prognostic value and therapeutic potential through molecular and clinical investigations.2025European journal of medical researchFree full text
  16. Development and verification of lymphangiogenesis score for prediction of prognosis and immune landscape in gastric cancer.2025Frontiers in immunologyFree full text
  17. Development and validation of nomogram for predicting pathological complete response to neoadjuvant chemotherapy and immunotherapy for locally advanced gastric cancer: a multicenter real-world study in China.2025Frontiers in immunologyFree full text
  18. Multiple programmed cell death patterns predict the prognosis and drug sensitivity in gastric cancer.2025Frontiers in immunologyFree full text
  19. The modified-Gustave Roussy immune score: assessing immune prognosis in advanced gastric cancer patients at baseline.2025Future oncology (London, England)Free full text
  20. FBXW2 inhibits the progression of gastric cancer via promoting β-catenin ubiquitylation.2025International journal of medical sciencesFree full text
  21. The safety and efficacy of neoadjuvant PD-1 inhibitor plus chemotherapy for patients with locally advanced gastric cancer: a systematic review and meta-analysis.2025International journal of surgery (London, England)Free full text
  22. MZT1 protects gastric cancer against glucose starvation through targeting NEDD1.2025Life sciences
  23. Pre-Chemotherapy D-Dimer Levels as Predictors of Survival Outcomes in Advanced Gastric Cancer.2025Medical science monitor : international medical journal of experimental and clinical researchFree full text
  24. Clinical Significance and Immune Infiltration Analyses of a Novel Nerve-Related lncRNA Signature in Gastric Cancer.2025Molecular biotechnology
  25. Nanoformulation-based drug delivery systems for the treatment of gastric cancer: recent developments and future prospects.2025Nanoscale horizons
  26. Single-cell and spatial transcriptomics implicate a prognostic function of tertiary lymphoid structures in gastric cancer.2025Nature communicationsFree full text
  27. Development and validation of a predictive model for the pathological upgrading of gastric low-grade intraepithelial neoplasia.2025World journal of gastroenterologyFree full text
  28. Defining Optimal Lymph Node Yield in Gastrectomy: A Real-World Cohort Analysis.2025World journal of surgical oncologyFree full text
  29. Single-cell dissection of prognostic architecture and immunotherap response in Helicobacter pylori infection-associated gastric cancer.2025eLifeFree full text
  30. Comprehensive Multiomics Analyses Establish the Optimal Prognostic Model for Resectable Gastric Cancer : Prognosis Prediction for Resectable GC.2024Annals of surgical oncology
  31. The impact of diabetes mellitus on short and long term outcomes in patients with gastric cancer following radical surgery: a retrospective cohort study with propensity score matching.2024BMC cancerFree full text
  32. Safety and efficacy of minimally invasive gastrectomy for older patients with gastric cancer after neoadjuvant chemotherapy and immunotherapy: a propensity score-matched analysis.2024BMC geriatricsFree full text
  33. Double tract reconstruction improves the quality of life and better maintain the BMI of patients with proximal gastric cancer.2024BMC surgeryFree full text
  34. The short-term efficacy of neoadjuvant SOX versus SOX plus immune checkpoint inhibitor following laparoscopic gastrectomy for locally advanced gastric cancer: a multicenter retrospective cohort study in China.2024Cancer immunology, immunotherapy : CIIFree full text
  35. Identification of gastric cancer stem cells with CD44 and Lgr5 double labelling and their initial roles on gastric cancer malignancy and chemotherapy resistance.2024Cell biology and toxicologyFree full text
  36. Trend of gastrointestinal and liver diseases in China: Results of the Global Burden of Disease Study, 2019.2024Chinese medical journalFree full text
  37. Role of submucosal injection in radiofrequency ablation of gastric low-grade dysplasia: Effects on symptoms and outcomes.2024Chinese medical journalFree full text
  38. A Novel Endoscopic Continuous Suture for Complete Mucosal Defect Closure After Gastric Endoscopic Submucosal Dissection in a Patient After Liver Transplantation.2024Digestive diseases and sciences
  39. Aspiration and coagulation to reduce risk of delayed bleeding after gastric endoscopic submucosal dissection (with video).2024Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  40. Flavonoids and Gastric Cancer Therapy: From Signaling Pathway to Therapeutic Significance.2024Drug design, development and therapyFree full text
  41. Application of through-the-scope twin clip for defect closure after gastric gastrointestinal stromal tumor transoral super minimally invasive surgery resection.2024EndoscopyFree full text
  42. An elastic traction device for facilitating endoscopic submucosal dissection of a submucosal tumor at the cardia.2024EndoscopyFree full text
  43. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer: A long way to go.2024European journal of cancer (Oxford, England : 1990)
  44. Proton pump inhibitors are not associated with fundic gland polyps - a systematic review that takes into consideration all known confounders.2024European journal of gastroenterology & hepatologyFree full text
  45. Histopathological and Immunohistochemical Mechanisms of Bone Marrow-Derived Mesenchymal Stem Cells in Reversion of Gastric Precancerous Lesions.2024Frontiers in bioscience (Landmark edition)
  46. Pre-treatment of hyponatremia as a biomarker for poor immune prognosis in advanced or metastatic gastric cancer: A retrospective case analysis.2024Human vaccines & immunotherapeuticsFree full text
  47. PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study.2024Investigational new drugsFree full text
  48. Clinicopathologic factors correlated with lymph node metastasis in gastric cancer: a retrospective cohort study involving 5606 patients.2024Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  49. Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial.2024Journal of hematology & oncologyRCTFree full text
  50. CircSCUBE3 Reduces the Anti-gastric Cancer Activity of Anti-PD-L1.2024Molecular biotechnology
  51. A new, simplified endoscopic scoring system for predicting clinical outcome in gastric low-grade intraepithelial neoplasia: the "e-cout system".2024Neoplasia (New York, N.Y.)Free full text
  52. CXCL10 and IL15 co-expressing chimeric antigen receptor T cells enhance anti-tumor effects in gastric cancer by increasing cytotoxic effector cell accumulation and survival.2024OncoimmunologyFree full text
  53. Akkermansia muciniphila-derived pentadecanoic acid enhances oxaliplatin sensitivity in gastric cancer by modulating glycolysis.2024Pharmacological research
  54. Clinical landscape and prognosis of patients with gastric cancer liver metastases: A nation-wide multicenter cohort study in China (RECORD study).2024Science bulletin
  55. Analysis of postoperative complications and long term survival following radical gastrectomy for patients with gastric cancer.2024Scientific reportsFree full text
  56. Safe and effective hybrid endoscopic submucosal dissection with ALL IN ONE snare in porcine gastric model (with video).2024Scientific reportsFree full text
  57. Gastric Cancer Assembloids Derived from Patient-Derived Xenografts: A Preclinical Model for Therapeutic Drug Screening.2024Small methods
  58. Endoscopic resection for the treatment of gastric gastrointestinal stromal tumors: a retrospective study from a large tertiary hospital in China.2024Surgical endoscopy
  59. Fibrin sealant for closure of mucosal penetration at the oesophagus or cardia during submucosal tunnelling endoscopic resection for gastrointestinal submucosal tumours.2024Surgical endoscopy
  60. Comparable long-term survival outcomes after endoscopic and gastrectomy treatment of pT1acN0M0 gastric adenocarcinoma in patients who met the expanded criteria.2024Surgical endoscopy
  61. Risk factors associated with lymph node metastasis in early-stage distal gastric cancer.2024World journal of surgery
  62. Oncology safety of proximal gastrectomy for advanced Siewert II adenocarcinoma of the esophagogastric junction compared with total gastrectomy: a propensity score-matched analysis.2024World journal of surgical oncologyFree full text
  63. Aspartoacylase promotes the process of tumour development and is associated with immune infiltrates in gastric cancer.2023BMC cancerFree full text
  64. MT1M regulates gastric cancer progression and stemness by modulating the Hedgehog pathway protein GLI1.2023Biochemical and biophysical research communications
  65. Prognostic value of the Lung Immune Prognostic Index for HER-2-negative metastatic gastric cancer.2023Biomarkers in medicine
  66. Estradiol cypionate inhibits proliferation and promotes apoptosis of gastric cancer by regulating AKT ubiquitination.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  67. LncRNA CCAT2 promotes malignant progression of metastatic gastric cancer through regulating CD44 alternative splicing.2023Cellular oncology (Dordrecht, Netherlands)Free full text
  68. Endoscopic resection for the treatment of non-gastric gastrointestinal stromal tumors: A retrospective study from a large tertiary hospital in China.2023Clinics and research in hepatology and gastroenterology
  69. Gastric inverted hyperplastic polyp with typical endoscopic feature.2023Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  70. A modified endoscopic full-thickness resection for gastrointestinal stromal tumors: A new closure technique based on the instruction of super minimally invasive surgery.2023EndoscopyFree full text
  71. KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer.2023European journal of cancer (Oxford, England : 1990)
  72. Postoperative ratio of C-reactive protein to albumin is an independent prognostic factor for gastric cancer.2023European journal of medical researchFree full text
  73. PD-1 inhibitors-based second-line therapy for metastatic gastric cancer.2023Frontiers in immunologyFree full text
  74. Circ-0000979 promotes the development of gastric carcinoma by sponging miR-136 and modulating SP1 mRNA expression level.2023Histology and histopathology
  75. Crystal structures and solution conformations of HtrA from Helicobacter pylori reveal pH-dependent oligomeric conversion and conformational rearrangements.2023International journal of biological macromolecules
  76. Inhibition of androgen receptor enhanced the anticancer effects of everolimus through targeting glucose transporter 12.2023International journal of biological sciencesFree full text
  77. Early assessment of circulating exosomal lncRNA-GC1 for monitoring neoadjuvant chemotherapy response in gastric cancer.2023International journal of surgery (London, England)Free full text
  78. Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial.2023JAMARCTFree full text
  79. A modified exposed endoscopic full-thickness resection: Traction-assisted resection while defect closing.2023Journal of digestive diseases
  80. L-kynurenine induces NK cell loss in gastric cancer microenvironment via promoting ferroptosis.2023Journal of experimental & clinical cancer research : CRFree full text
  81. Risk Factor Analysis of Gastroparesis Syndrome in 2652 Patients with Radical Distal Gastrectomy.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  82. Gastrointestinal Fistula in Radical Distal Gastrectomy: Case-Control Study from a High-Volume Hospital.2023Journal of laparoendoscopic & advanced surgical techniques. Part A
  83. The Prognostic Value of the Prognostic Nutritional Index in Patients with Advanced or Metastatic Gastric Cancer Treated with Immunotherapy.2023NutrientsFree full text
  84. Natural products targeting signaling pathways associated with regulated cell death in gastric cancer: Recent advances and perspectives.2023Phytotherapy research : PTR
  85. PD-L1 expression downregulation by RNF43 in gastric carcinoma enhances antitumour activity of T cells.2023Scandinavian journal of immunology
  86. Surgical starting time of the day and survival in gastric cancer.2023Scientific reportsFree full text
  87. Dual-branch hybrid network for lesion segmentation in gastric cancer images.2023Scientific reportsFree full text
  88. A novel detection technology for early gastric cancer based on Raman spectroscopy.2023Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  89. Five-year long-term comparison of robotic and laparoscopic gastrectomy for gastric cancer: a large single-center cohort study.2023Surgical endoscopy
  90. Endoscopic resection of gastric low-grade dysplasia with high risk factors is associated with decreased advanced neoplasia: a single-center retrospective cohort study.2023Surgical endoscopy
  91. Early Outcomes of Different Reconstruction Procedures in Radical Distal Gastrectomy: A Retrospective Propensity Score Matching Study.2023Surgical laparoscopy, endoscopy & percutaneous techniques
  92. Upregulation of OTX2-AS1 is Associated With Immune Infiltration and Predicts Prognosis of Gastric Cancer.2023Technology in cancer research & treatmentFree full text
  93. Hotspots and frontiers of the relationship between gastric cancer and depression: A bibliometric study.2023World journal of gastroenterologyFree full text
  94. Expression characteristics of peripheral lymphocyte programmed death 1 and FoxP3+ Tregs in gastric cancer during surgery and chemotherapy.2023World journal of gastroenterologyFree full text
  95. Plasma exosomal hsa_circ_0079439 as a novel biomarker for early detection of gastric cancer.2023World journal of gastroenterologyFree full text
  96. The Role of lncRNA PVT1 and hsa-miR-30a-3p in the Development of Gastric Cancer.2022Annals of clinical and laboratory science
  97. Diagnostic accuracy of linked colour imaging versus white light imaging for early gastric cancers: a prospective, multicentre, randomized controlled trial study.2022Annals of medicineRCTFree full text
  98. Prognostic and clinical significance of HER-2 low expression in early-stage gastric cancer.2022BMC cancerFree full text
  99. Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors.2022BMC cancerFree full text
  100. Relationship between HER2 overexpression and long-term outcomes of early gastric cancer: a prospective observational study with a 6-year follow-up.2022BMC gastroenterologyFree full text
  101. Rspondin-1 contributes to the progression and stemness of gastric cancer by LGR5.2022Biochemical and biophysical research communications
  102. Astragaloside IV exhibits anti-tumor function in gastric cancer via targeting circRNA dihydrolipoamide S-succinyltransferase (circDLST)/miR-489-3p/ eukaryotic translation initiation factor 4A1(EIF4A1) pathway.2022BioengineeredFree full text
  103. MiR-378a-3p acts as a tumor suppressor in gastric cancer via directly targeting RAB31 and inhibiting the Hedgehog pathway proteins GLI1/2.2022Cancer biology & medicineFree full text
  104. Health-related quality of life after super minimally invasive surgery and proximal gastrectomy for early-stage adenocarcinoma of the esophagogastric junction: a propensity score-matched study.2022Chinese medical journalFree full text
  105. Risk factors of major intraoperative bleeding and postoperative bleeding associated with endoscopic submucosal dissection for gastric neoplasms.2022Chinese medical journalFree full text
  106. Effect of Postoperative ω-3 Fatty Acid Immunonutritional Therapy on NK Cell Gene Methylation in Elderly Patients with Gastric Cancer.2022Current medical scienceRCT
  107. SPAG5 Activates PI3K/AKT Pathway and Promotes the Tumor Progression and Chemo-Resistance in Gastric Cancer.2022DNA and cell biology
  108. Circulating exosomal gastric cancer-associated long noncoding RNA1 as a noninvasive biomarker for predicting chemotherapy response and prognosis of advanced gastric cancer: A multi-cohort, multi-phase study.2022EBioMedicineFree full text
  109. Construction of a nomogram to predict the survival of metastatic gastric cancer patients that received immunotherapy.2022Frontiers in immunologyFree full text
  110. Effect of Early Enteral Nutrition Support Combined with Chemotherapy on Related Complications and Immune Function of Patients after Radical Gastrectomy.2022Journal of healthcare engineeringFree full text
  111. Construction of gastric cancer patient-derived organoids and their utilization in a comparative study of clinically used paclitaxel nanoformulations.2022Journal of nanobiotechnologyFree full text
  112. Assessment of deep learning assistance for the pathological diagnosis of gastric cancer.2022Modern pathology : an official journal of the United States and Canadian Academy of Pathology, IncFree full text
  113. Outcomes of simultaneous endoscopic submucosal dissection for synchronous multiple gastric neoplastic lesions: a retrospective comparative study.2022Surgical endoscopy
  114. Clinical outcomes of endoscopic resection for the treatment of gastric gastrointestinal stromal tumors originating from the muscularis propria: a 7-year experience from a large tertiary center in China.2022Surgical endoscopy
  115. Comparable long-term outcomes after endoscopic therapy and gastrectomy of early adenocarcinoma of esophagogastric junction: a population-based study.2022Surgical endoscopy
  116. Defining the impact of platelet-to-lymphocyte ratio on patient survival with gastric neuroendocrine neoplasm: a retrospective cohort analysis.2022World journal of surgical oncologyFree full text
  117. Prognostic value of lymph node density on cancer staging system for gastric cancer without distal metastasis: a population-based analysis of SEER database.2022World journal of surgical oncologyFree full text
  118. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-I2021BMC cancerFree full text
  119. Comparison of short-term outcomes and quality of life in totally laparoscopic distal gastrectomy and totally robotic distal gastrectomy for clinical stage I-III gastric cancer: study protocol for a multi-institutional randomised clinical tr2021BMJ openFree full text
  120. Knockdown of circBFAR inhibits proliferation and glycolysis in gastric cancer by sponging miR-513a-3p/hexokinase 2 axis.2021Biochemical and biophysical research communications
  121. GRSF1 promotes tumorigenesis and EMT-mediated metastasis through PI3K/AKT pathway in gastric cancer.2021Biochemical and biophysical research communications
  122. LncRNA-SNHG7 interferes with miR-34a to de-sensitize gastric cancer cells to cisplatin.2021Cancer biomarkers : section A of Disease markersFree full text
  123. Characteristics of metachronous gastric neoplasms after curative endoscopic submucosal dissection for early gastric neoplasms.2021Chinese medical journalFree full text
  124. Association of the pretreatment lung immune prognostic index with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors.2021Clinics and research in hepatology and gastroenterology
  125. Plasma Exosomal CircNEK9 Accelerates the Progression of Gastric Cancer via miR-409-3p/MAP7 Axis.2021Digestive diseases and sciences
  126. Integrated Analysis of lncRNA-Associated ceRNA Network Identifies Two lncRNA Signatures as a Prognostic Biomarker in Gastric Cancer.2021Disease markersFree full text
  127. Magnetic multidirectional anchor-guided endoscopic submucosal tunnel dissection for large gastric lesions.2021Endoscopy
  128. CircRNAs in gastric cancer: current research and potential clinical implications.2021FEBS letters
  129. Salivary Microbiota for Gastric Cancer Prediction: An Exploratory Study.2021Frontiers in cellular and infection microbiologyFree full text
  130. Tumor suppressor ATP4B serve as a promising biomarker for worsening of gastric atrophy and poor differentiation.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  131. Does Endoscopic Screening Really Not Alter the Incidence of Gastric Cancer?2021Gastroenterology
  132. Dissecting transcriptional heterogeneity in primary gastric adenocarcinoma by single cell RNA sequencing.2021GutFree full text
  133. Role of circular RNAs and long non‑coding RNAs in the clinical translation of gastric cancer (Review).2021International journal of molecular medicineFree full text
  134. A predictive risk-scoring model for multiple synchronous early gastric cancers or gastric dysplasia before initial endoscopic resection.2021Journal of digestive diseasesRCT
  135. Impact of Lymph Nodes Examined on Survival in ypN0 Gastric Cancer Patients: a Population-Based Study.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  136. Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer.2021Journal of immunology researchFree full text
  137. MiR-144-3p inhibits gastric cancer progression and stemness via directly targeting GLI2 involved in hedgehog pathway.2021Journal of translational medicineFree full text
  138. Endoscopic versus surgical resection in the management of gastric schwannomas.2021Surgical endoscopy
  139. Safety and feasibility of total laparoscopic radical resection of Siewert type II gastroesophageal junction adenocarcinoma through the left diaphragm and left thoracic auxiliary hole.2021World journal of surgical oncologyFree full text
  140. Total laparoscopic transabdominal-transdiaphragmatic approach for treating Siewert II tumors: a prospective analysis of a case series.2021World journal of surgical oncologyFree full text
Chinese-language papers (not in the count)24
  1. [Gastric adenocarcinoma complicated by subarachnoid hemorrhage and cerebral infarction: a rare case of Trousseau syndrome and literature review].2025Zhonghua nei ke za zhi
  2. [Analysis of the efficacy and influencing factors of immunotherapy in gastric cancer liver metastasic patients].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  3. [Short-term effects and safety outcomes of the combination of tislelizumab and neoadjuvant chemotherapy in the perioperative treatment of locally advanced gastric cancer].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [Risk factors and nomogram construction for predicting long-term survival in hepatoid adenocarcinoma of the stomach].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. [Function-preserving gastrectomy for locally advanced gastric cancer after neoadjuvant immunotherapy].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  6. [Progress and implementing of novel surgical concepts and techniques in patients with resectable gastric cancer liver metastasis].2024Zhonghua wai ke za zhi [Chinese journal of surgery]
  7. [Quality control of digestive tract reconstruction after robotic gastrectomy].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  8. [Key updates and interpretation of the ninth version of AJCC staging system for neuroendocrine tumors of the stomach].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  9. [Research progress and future trends of early-onset gastric cancer].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  10. [Computer-vision-based artificial intelligence for detection and recognition of instruments and organs during radical laparoscopic gastrectomy for gastric cancer: a multicenter study].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  11. [Diagnostics and treatment challenges and research progress in early-onset gastric cancer].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  12. [Prevalence and risk factors of sarcopenia after radical gastrectomy for gastric cancer].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  13. [Establishment and validation of a nomogram for predicting prognosis of gastric neuroendocrine neoplasms based on data from 490 cases in a single center].2023Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
  14. [Analysis of clinicopathological characteristics, therapeutic strategy and prognosis of 501 patients with gastric neuroendocrine neoplasms attending a single center].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  15. [Preoperative evaluation of gastric cancer and risk factors for postoperative complications].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  16. [Current status and future prospects of robotic surgical system in radical gastrectomy for gastric cancer].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  17. [Several issues on surgical treatment for adenocarcinoma of esophagogastric junction].2022Zhonghua wai ke za zhi [Chinese journal of surgery]
  18. [Factors influencing super-long hospital stays in patients undergoing radical gastrectomy in the age of enhanced recovery after surgery].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  19. [Preliminary experience with double-tract reconstruction combined with π-shaped esophagojejunal anastomosis after total laparoscopic proximal gastrectomy for the treatment of adenocarcinoma of esophagogastric junction].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  20. [A comparative study on short-term outcomes and quality of life for gastric cancer patients between totally laparoscopic total gastrectomy using an endoscopic linear stapler and laparoscopic-assisted total gastrectomy using a circular stapl2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  21. [A nomogram for predicting lymph node metastasis in early gastric cancer].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  22. [A novel classification and strategy choice of digestive tract reconstruction procedures after function-preserving gastrectomy for early gastric caner].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  23. [Risk factors of postoperative complication after total gastrectomy in advanced gastric cancer patients receiving neoadjuvant chemotherapy].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  24. [Consensus and controversy for the surgical advance of gastric cancer liver metastasis].2021Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status65
  1. The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled TrialRecruitingNCT07212933Lead sponsorPhase 2Start 2025-07
  2. Helicobacter Pylori Infection Status and Pathological Features for Predicting Gastric Cancer Biological Behavior and Prognosis: A Real-World Observational StudyRecruitingNCT07724496Lead sponsorStart 2024-01
  3. Oxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric CancerRecruitingNCT04483076Lead sponsorPhase 3Start 2021-01
  4. Different Cycles of Neoadjuvant PD-1 Blockades + Chemotherapy for Advanced Gastric CancerCompletedNCT06798376Lead sponsorStart 2025-01
  5. Multimodal Prehabilitation for Resectable Gastric CancerCompletedNCT05714878Lead sponsorN/AStart 2023-03
  6. Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and ChemotherapyCompletedNCT06202781Lead sponsorStart 2022-07
  7. Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric CancerStatus unknownNCT04367025Lead sponsorPhase 2Start 2020-05
  8. Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04182724Lead sponsorPhase 1/Phase 2Start 2019-11
  9. Neo-adjuvant Chemotherapy Evluation in Gastric Cancer Patients Based on Circulating Exosomal LncRNA-GC1Status unknownNCT05647941Lead sponsorStart 2018-01
  10. Use of a Liquid Biopsy Signature to Detect Early-onset Gastric CancerCompletedNCT06023121Lead sponsorStart 2018-01
  11. Laparoscopic Versus Open Gastrectomy With Splenic Hilum Lymph Nodes DissectionStatus unknownNCT02980861Lead sponsorPhase 3Start 2017-01
  12. 3D Versus 2D Laparoscopic Total Gastrectomy With Splenic Hilum Lymph Nodes DissectionStatus unknownNCT02984787Lead sponsorPhase 3Start 2017-01
  13. The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric CancerStatus unknownNCT03007446Lead sponsorPhase 2Start 2016-11
  14. Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301)Status unknownNCT02596256Lead sponsorPhase 2Start 2016-04
  15. T- XELOX in HER2-positive Stage III Gastric Cancer After D2 GastrectomyStatus unknownNCT02250209Lead sponsorPhase 2Start 2014-07
  16. Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96Status unknownNCT02317471Lead sponsorPhase 1/Phase 2Start 2014-11
  17. Gastric Cancer Liver Metastasis Cohort of ChinaStatus unknownNCT04574245Lead sponsorStart 2010-01
  18. Study of S-1 and Oxaliplatin as Neoadjuvant Chemotherapy for Locally Advanced Gastric CancerStatus unknownNCT01090505Lead sponsorPhase 2Start 2009-11
  19. Neoadjuvant Bev Plus DOF vs DOF in LAGC and Its Association With Circulating Tumor CellCompletedNCT02048540Lead sponsorPhase 1/Phase 2Start 2009-02
  20. Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric CancerRecruitingNCT07392346Lead (inferred)Phase 2Start 2025-12
  21. EGPSS for Weight Management in an in Vivo Human ModelEnrolling by invitationNCT07186959Lead (inferred)N/AStart 2024-07
  22. Prospective Observational Cohort StudyNot yet recruitingNCT06493448Lead (inferred)Start 2024-07
  23. Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric CancerStatus unknownNCT06284746Lead (inferred)Phase 2Start 2023-10
  24. Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer, Esophageal Cancer and Liver CancerStatus unknownNCT05192460Lead (inferred)N/AStart 2022-03
  25. NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid TumorsStatus unknownNCT05583201Lead (inferred)Early phase 1Start 2022-10
  26. Effects of Abdominal Nerve Block on Postoperative Recovery in Patients Undergoing Gastrointestinal SurgeryStatus unknownNCT04147481Lead (inferred)N/AStart 2019-10
  27. Prospectively Predict the Immunotherapy Response of Gastric Cancer Based on Circulating Exosomal LncRNA-GC1 BiopsyCompletedNCT05334849Lead (inferred)Start 2018-11
  28. SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric CancerStatus unknownNCT01583361Lead (inferred)Phase 3Start 2012-03
  29. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion TherapyRecruitingNCT07789184Study sitePhase 3Start 2026-12
  30. A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer PatientsRecruitingNCT07103668Study sitePhase 3Start 2025-08
  31. KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line TherapyRecruitingNCT05427383Study sitePhase 2/Phase 3Start 2022-04
  32. Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal CancerActive, not recruitingNCT06247956Study sitePhase 2Start 2024-03
  33. LCI in Chronic Atrophic Gastritis and Early Gastric CancerStatus unknownNCT06152263Study siteStart 2023-09
  34. Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic AdenocarcinomaStatus unknownNCT05275062Study siteEarly phase 1Start 2022-02
  35. A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid TumorsCompletedNCT05173142Study sitePhase 1/Phase 2Start 2022-01
  36. Endoscopic Vital Nerve Staining in Gastrointestinal DiseasesStatus unknownNCT05232357Study siteEarly phase 1Start 2022-03
  37. A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid TumorsTerminatedNCT05427396Study sitePhase 1Start 2022-07
  38. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  39. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  40. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer DiagnosisStatus unknownNCT04440605Study siteStart 2020-07
  41. KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction CancerCompletedNCT03925974Study sitePhase 2Start 2019-06
  42. A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric CancerStatus unknownNCT04139135Study sitePhase 3Start 2019-12
  43. Study of Faecal Bacteria Detection in Early Screening and Diagnosis of GCStatus unknownNCT04638959Study siteStart 2019-09
  44. Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric CancersStatus unknownNCT03468712Study siteN/AStart 2018-03
  45. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction CancerCompletedNCT03694522Study sitePhase 2Start 2018-09
  46. Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)CompletedNCT03615326Study sitePhase 3Start 2018-10
  47. Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric CancerCompletedNCT03745170Study sitePhase 3Start 2018-12
  48. Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810Status unknownNCT03260179Study sitePhase 1Start 2017-08
  49. Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric CancerStatus unknownNCT03273920Study siteN/AStart 2017-09
  50. BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction CarcinomaCompletedNCT03469557Study sitePhase 2Start 2017-07
  51. Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric CancerTerminatedNCT02867839Study sitePhase 3Start 2017-04
  52. A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal CancerCompletedNCT02898077Study sitePhase 3Start 2017-03
  53. Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)TerminatedNCT03019588Study sitePhase 3Start 2017-02
  54. Nasal Endoscopic Screening and Risk Assessment for Early Gastric CancerStatus unknownNCT04989153Study siteStart 2016-03
  55. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)Status unknownNCT02461407Study sitePhase 2/Phase 3Start 2015-06
  56. Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2Status unknownNCT02356276Study sitePhase 3Start 2015-05
  57. Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric CancerStatus unknownNCT02537171Study sitePhase 3Start 2015-07
  58. Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric CancerStatus unknownNCT02378389Study sitePhase 1Start 2014-09
  59. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction CancerCompletedNCT02178956Study sitePhase 3Start 2014-10
  60. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric CancerCompletedNCT01774786Study sitePhase 3Start 2013-06
  61. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04
  62. Study of S1 Efficacy and Toxicity as Second-line Treatment on Inoperable or Advanced Gastric CancersStatus unknownNCT01650766Study siteStart 2012-02
  63. Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)Status unknownNCT01609309Study sitePhase 3Start 2012-09
  64. A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric CancerTerminatedNCT01641939Study sitePhase 2/Phase 3Start 2012-09
  65. Taxanes or Platinum in Combination With Capecitabine Followed by Capecitabine Alone as First Line Treatment for Patients With Advanced Adenocarcinoma of Stomach or Esophagogastric JunctionStatus unknownNCT01468389Study sitePhase 3Start 2011-11

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 3 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 1.9%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 1120242025: 002025

9 hospitals in Beijing for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicinePathology / laboratory medicinePediatrics

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 2 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 0020242025: 002025

10 hospitals in Beijing for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmologyENT / head & neck surgery

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 12 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.5%.

Papers led
12
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 3320212022: 0020222023: 2220232024: 3320242025: 332025

48 hospitals in Beijing for osteosarcoma742 hospitals in China for osteosarcoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
    Phase
    Phase 2
    Started
    2023-06
    Registry
    NCT05830123

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Shanghai, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led12
  1. Co-Delivery of Cisplatin and Curcumin via ROS-Responsive Nanoparticles to Activate the cGAS-STING Pathway for Osteosarcoma Metalloimmunotherapy.2026Advanced healthcare materials
  2. Unveiling the role of the extracellular matrix in the osteosarcoma tumor microenvironment through integrated transcriptomics and experimental validation.2025Cancer gene therapy
  3. Adamantinoma‑like Ewing Sarcoma of Head and Neck: A Clinicopathologic Study of Three Cases Including One EWSR1-Negative Case with NF1 Mutation.2025Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  4. DOT1L suppressed the proliferation of osteosarcoma cell line via modulating SYK/EGFR/P53 and SHP2-induced STING-NLRP3-pyroptosis signaling.2025Scientific reports
  5. Identifying Genetic Signatures Associated with Oncogene-Induced Replication Stress in Osteosarcoma and Screening for Potential Targeted Drugs.2024Biochemical genetics
  6. Integrated transcriptomic analysis systematically reveals the heterogeneity and molecular characterization of cancer-associated fibroblasts in osteosarcoma.2024Gene
  7. Mn, N co-doped CDs as a fluorescent nanosensing platform for the detection of tannic acid and hafnium ion and in vitro fluorescence imaging of U2OS osteosarcoma cells.2024Mikrochimica acta
  8. Hsa_circ_0000591 drives osteosarcoma glycolysis and progression by sequestering miR-194-5p and elevating HK2 expression.2023Clinical and experimental pharmacology & physiology
  9. Neoadjuvant Chemotherapy and Expandable Prosthesis Reconstruction to Treat Osteosarcoma around the Knee in Children.2023Orthopaedic surgery
  10. A new antisarcoma strategy: multisubtype heat shock protein/peptide immunotherapy combined with PD-L1 immunological checkpoint inhibitors.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  11. Hematopoietic cell kinase enhances osteosarcoma development via the MEK/ERK pathway.2021Journal of cellular and molecular medicine
  12. A novel small-molecule antagonist enhances the sensitivity of osteosarcoma to cabozantinib in vitro and in vivo by targeting DNMT-1 correlated with disease severity in human patients.2021Pharmacological research
Earlier papers (2016–2020)9
  1. GRM4 inhibits the proliferation, migration, and invasion of human osteosarcoma cells through interaction with CBX4.2020Bioscience, biotechnology, and biochemistry
  2. Long Noncoding RNA SERTAD2-3 Inhibits Osteosarcoma Proliferation and Migration by Competitively Binding miR-29c.2020Genetic testing and molecular biomarkers
  3. Circular RNA 0086996 regulates growth and migration of osteosarcoma cells via miR-125b-5p.2020Pathology, research and practice
  4. [Application of rotationplasty in treatment of osteosarcoma of distal femur in children].2020Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  5. The multidisciplinary treatment of osteosarcoma of the proximal tibia: a retrospective study.2018BMC musculoskeletal disorders
  6. Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study.2018Cancer biology & therapy
  7. Up-regulation of long noncoding RNA CCAL predicts poor patient prognosis and promotes tumor metastasis in osteosarcoma.2017The International journal of biological markers
  8. Magnetic resonance imaging of osteosarcoma using a bis(alendronate)-based bone-targeted contrast agent.2016Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  9. Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance.2016Chinese journal of cancer
All its trials on ClinicalTrials.gov, any status1
  1. ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other SarcomasRecruitingNCT05830123Study sitePhase 2Start 2023-06

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 7 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 1.3%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 3320242025: 112025

23 hospitals in Beijing for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Novel Two-Tooth Clip for ESD and EFTR of GIST
    Phase
    N/A
    Started
    2026-04
    Registry
    NCT07581977

    Age 18 years to 85 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  2. Recruiting
    A Study of HQP1351 in Patients With GIST or Other Solid Tumors
    Phase
    Phase 1
    Started
    2018-07
    Registry
    NCT03594422

    Age 12 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatology
Papers it led7
  1. The maximum transverse diameter: an effective indicator for predicting peroral en bloc retrieval rate of mesenchymal tumors after endoscopic resection.2025Surgical endoscopy
  2. Application of through-the-scope twin clip for defect closure after gastric gastrointestinal stromal tumor transoral super minimally invasive surgery resection.2024EndoscopyFree full text
  3. Endoscopic resection of gastrointestinal stromal tumors.2024Journal of digestive diseases
  4. Endoscopic resection for the treatment of gastric gastrointestinal stromal tumors: a retrospective study from a large tertiary hospital in China.2024Surgical endoscopy
  5. Endoscopic resection for the treatment of non-gastric gastrointestinal stromal tumors: A retrospective study from a large tertiary hospital in China.2023Clinics and research in hepatology and gastroenterology
  6. A modified endoscopic full-thickness resection for gastrointestinal stromal tumors: A new closure technique based on the instruction of super minimally invasive surgery.2023EndoscopyFree full text
  7. Clinical outcomes of endoscopic resection for the treatment of gastric gastrointestinal stromal tumors originating from the muscularis propria: a 7-year experience from a large tertiary center in China.2022Surgical endoscopy
Earlier papers (2016–2020)7
  1. Comparison between endoscopic and surgical resection of gastric GI stromal tumors.2020Gastrointestinal endoscopy
  2. Endoscopic resection: Comparable with surgical resection for treating small-sized gastric GI stromal tumors?2020Gastrointestinal endoscopy
  3. [Efficacy comparison between laparoscopy and open surgery in the treatment of gastric gastrointestinal stromal tumors larger than 2 cm using multicenter propensity score matching method].2020Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor.2018Future oncology (London, England)
  5. Identification of key genes related to high-risk gastrointestinal stromal tumors using bioinformatics analysis.2018Journal of cancer research and therapeutics
  6. [Imaging characteristics of gastrointestinal neoplastic acute abdomen].2018Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  7. Submucosal Tunneling Endoscopic Resection for the Treatment of Gastrointestinal Submucosal Tumors Originating from the Muscularis Propria Layer.2017Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
All its trials on ClinicalTrials.gov, any status9
  1. A Novel Two-Tooth Clip for ESD and EFTR of GISTRecruitingNCT07581977Study siteN/AStart 2026-04
  2. A Study of HQP1351 in Patients With GIST or Other Solid TumorsRecruitingNCT03594422Study sitePhase 1Start 2018-07
  3. Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of ImatinibTerminatedNCT04409223Study sitePhase 3Start 2020-09
  4. A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)CompletedNCT04282980Study sitePhase 2Start 2020-04
  5. A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With ImatinibCompletedNCT04633122Study sitePhase 2Start 2020-11
  6. A Study of CS3007 in Subjects With Gastrointestinal Stromal TumorCompletedNCT04254939Study sitePhase 1/Phase 2Start 2019-08
  7. (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GISTCompletedNCT03465722Study sitePhase 3Start 2018-03
  8. A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GISTStatus unknownNCT02776878Study siteN/AStart 2016-05
  9. Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal TumorCompletedNCT00793871Study sitePhase 4Start 2008-11

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

24 hospitals in Beijing for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

17 hospitals in Beijing for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine
Papers it led1
  1. Adamantinoma‑like Ewing Sarcoma of Head and Neck: A Clinicopathologic Study of Three Cases Including One EWSR1-Negative Case with NF1 Mutation.2025Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
All its trials on ClinicalTrials.gov, any status1
  1. Anlotinib and Irinotecan for Ewing SarcomaStatus unknownNCT03416517Study sitePhase 1/Phase 2Start 2018-01

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 5 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.3%.

Papers led
5
2021–2025
Trials led
5
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 1120242025: 112025

15 hospitals in Beijing for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
    Phase
    Phase 1
    Started
    2026-09
    Registry
    NCT07620275

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General Hospital; 2 listed hospitals as study sitesBeijing, Tianjin

  2. Recruiting
    Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07489534

    Age 14 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskStem cell transplantKidney & bone complications
Departments in papersRadiology / nuclear medicinePathology / laboratory medicine
Papers it led5
  1. HLA-mismatched stem cell microtransplant prolonged overall survival and promoted immunological reconstitution for multiple myeloma.2025Frontiers in immunologyFree full text
  2. Clotrimazole inhibits growth of multiple myeloma cells in vitro via G0/G1 arrest and mitochondrial apoptosis.2024Scientific reportsFree full text
  3. Magnetic Resonance Imaging combined with Computed Tomography in the Diagnosis of Multiple Myeloma and the Killing Effect of Doxorubicin Nano-drug Delivery System on Myeloma Cells.2022Cellular and molecular biology (Noisy-le-Grand, France)
  4. Percutaneous vertebroplasty combined with chemotherapy in the treatment of multiple myeloma patients with vertebral compression fractures.2022Chinese medical journalFree full text
  5. Upregulation of ATIC in multiple myeloma tissues based on tissue microarray and gene microarrays.2021International journal of laboratory hematology
Chinese-language papers (not in the count)8
  1. [Effective Salvage Mobilization of Peripheral Blood Stem Cells with High-Dose Etoposide in Newly Diagnosed Multiple Myeloma Patients Who Failed Initial Mobilization with High-Dose Cyclophosphamide].2025Zhongguo shi yan xue ye xue za zhi
  2. [Analysis of the efficacy and safety of bone disease treatment in patients with newly diagnosed multiple myeloma treated with denosumab or zoledronic acid].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  3. [Omics Analysis of Ferroptosis and Establishment of Prognostic Model for multiple myeloma Patients].2023Zhongguo shi yan xue ye xue za zhi
  4. [Construction of a Prognostic Model of Multiple Myeloma Based on Metabolism-Related Genes].2023Zhongguo shi yan xue ye xue za zhi
  5. [Daratumumab maintenance after autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  6. [Autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma with severe renal impairment: a report of 5 cases and literature review].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  7. [The Effect of Improved Culturing Method on the Detection Rate of Chromosome Karyotyping in Multiple Myeloma].2022Zhongguo shi yan xue ye xue za zhi
  8. [Analysis of Factors Influencing Autologous Peripheral Blood Stem Cells Mobilization in Patients with Lymphoma and Multiple Myeloma].2021Zhongguo shi yan xue ye xue za zhi
All its trials on ClinicalTrials.gov, any status9
  1. Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMARecruitingNCT07620275Lead sponsorPhase 1Start 2026-09
  2. Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple MyelomaStatus unknownNCT04162119Lead sponsorPhase 2Start 2019-07
  3. A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple MyelomaStatus unknownNCT03767751Lead sponsorPhase 1/Phase 2Start 2018-12
  4. Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138Status unknownNCT01886976Lead sponsorPhase 1/Phase 2Start 2013-06
  5. Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal DysfunctionRecruitingNCT07489534Lead (inferred)Phase 2Start 2025-09
  6. Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid TherapyCompletedNCT02609828Study sitePhase 3Start 2015-10
  7. Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple MyelomaCompletedNCT01818752Study sitePhase 3Start 2013-07
  8. Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 YearCompletedNCT02348528Study sitePhase 2Start 2012-09
  9. Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple MyelomaCompletedNCT01593410Study sitePhase 2Start 2010-08

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led no English-language PubMed papers on B-cell acute lymphoblastic leukaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
12
any status, ClinicalTrials.gov
Open trials led
6
recruiting or about to
Open trials as a site
0
led by another institution

10 hospitals in Beijing for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 6

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Registry
    NCT07575919

    Age 18 years to 85 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  2. Recruiting
    Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Registry
    NCT07575971

    Age 18 years to 85 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  3. Recruiting
    TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
    Phase
    Phase 1/Phase 2
    Started
    2025-02
    Registry
    NCT06481735

    Age 16 years to 70 years (registered criteria)

    Led by Chinese PLA General Hospital; 3 listed hospitals as study sitesBeijing, Tianjin

  4. Recruiting
    BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL
    Phase
    Phase 1/Phase 2
    Started
    2025-06
    Registry
    NCT07008885

    Age 18 years to 70 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  5. Recruiting
    Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL
    Phase
    Phase 1
    Started
    2024-12
    Registry
    NCT07677878

    Age 18 years to 70 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  6. Recruiting
    Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen
    Phase
    Phase 2
    Started
    2021-12
    Registry
    NCT05088226

    Age 12 years to 65 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Chinese-language papers (not in the count)1
  1. [Efficacy and Safety of Blinatumomab in Adult Patients with B-Cell Acute Lymphoblastic Leukemia].2025Zhongguo shi yan xue ye xue za zhi
All its trials on ClinicalTrials.gov, any status14
  1. BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALLRecruitingNCT07008885Lead sponsorPhase 1/Phase 2Start 2025-06
  2. TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALLRecruitingNCT06481735Lead sponsorPhase 1/Phase 2Start 2025-02
  3. Ruxolitinib and Chidamide Intensified Bu/CY Conditioning RegimenRecruitingNCT05088226Lead sponsorPhase 2Start 2021-12
  4. CAR-T-19 Cells for Patients With CD19+ Relapse/Refractory B-ALLStatus unknownNCT05270772Lead sponsorPhase 1Start 2021-02
  5. A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular ImmunotherapyStatus unknownNCT03754764Lead sponsorPhase 1/Phase 2Start 2018-11
  6. Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20CompletedNCT03097770Lead sponsorPhase 1/Phase 2Start 2017-04
  7. Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22Status unknownNCT03185494Lead sponsorPhase 1/Phase 2Start 2017-08
  8. Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to ChemotherapyStatus unknownNCT01735604Lead sponsorPhase 1/Phase 2Start 2013-01
  9. Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19Status unknownNCT01864889Lead sponsorN/AStart 2013-04
  10. Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic LeukemiaRecruitingNCT07575971Lead (inferred)Phase 1/Phase 2Start 2026-01
  11. Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALLRecruitingNCT07575919Lead (inferred)Phase 1/Phase 2Start 2026-01
  12. Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALLRecruitingNCT07677878Lead (inferred)Phase 1Start 2024-12
  13. Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell LymphomaStatus unknownNCT03281551Study sitePhase 1Start 2017-10
  14. A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALLStatus unknownNCT03018093Study sitePhase 1Start 2017-01

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 1 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

6 hospitals in Beijing for aplastic anaemia63 hospitals in China for aplastic anaemia

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Enrolling by invitation
    Phase I Clinical Study of Haplo-HSCT Combined With Hypoxic 3D-Cultured Umbilical Cord MSC for the Treatment of SAA
    Phase
    Phase 1/Phase 2
    Started
    2022-08
    Registry
    NCT07299123

    Age 6 years to 60 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesStem cell transplantChildren
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 2 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

11 hospitals in Beijing for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection
    Phase
    Phase 1
    Started
    2023-08
    Registry
    NCT06135922

    Age 1 year to 60 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEBV & infection triggersGenetics & inherited formsChildren
Departments in papersNeurologyPediatrics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led no English-language PubMed papers on beta thalassaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

10 hospitals in Beijing for beta thalassaemia157 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Chinese-language papers (not in the count)1
  1. [Study on Thalassemia in Han Population in Sanya of Hainan Province].2022Zhongguo shi yan xue ye xue za zhi
Earlier papers (2016–2020)1
  1. [Genotype Analysis of Patients with Thalassemia in Sanya Area of Hainan Province in China].2018Zhongguo shi yan xue ye xue za zhi

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 1 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

15 hospitals in Beijing for haemophilia A160 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征

Led 1 of the 27 English-language PubMed papers on atypical haemolytic uraemic syndrome with an author in mainland China, 2021–2025: 3.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

6 hospitals in Beijing for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome

No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 12 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 2.5%.

Papers led
12
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 4420222023: 3320232024: 1120242025: 222025

12 hospitals in Beijing for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study
    Phase
    Phase 4
    Started
    2026-02
    Registry
    NCT07410039

    Age 18 years to 65 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  2. Not yet recruiting
    The Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder.
    Phase
    Early phase 1
    Started
    2026-05
    Registry
    NCT07592754

    Age 18 years to 65 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  3. Recruiting
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06413654

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesAntibodies & diagnosisAcute attack treatmentOptic nerve & vision
Departments in papersNeurologyOphthalmology / neuro-ophthalmologyPathology / laboratory medicinePediatrics
Papers it led12
  1. Intravitreal delivery of NMO-IgG causes primary retinal damage in the absence of optic nerve injury.2025Journal of neuroinflammationFree full text
  2. Nomogram for the prediction of relapse factors in patients with neuromyelitis optica spectrum disorder during rituximab treatment.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  3. Rituximab maintenance treatment outcomes in patients with relapsing neuromyelitis optica spectrum disorder: a monocentric retrospective analysis.2024Acta neurologica Belgica
  4. Decipher potential biomarkers of diagnosis and disease activity for NMOSD with AQP4 using LC-MS/MS and Simoa.2023International immunopharmacology
  5. ACT001 Relieves NMOSD Symptoms by Reducing Astrocyte Damage with an Autoimmune Antibody.2023Molecules (Basel, Switzerland)Free full text
  6. Symptomatic trigeminal autonomic cephalalgias in neuromyelitis optica spectrum disorders.2023Multiple sclerosis and related disorders
  7. Safety and efficacy of plasma exchange treatment in children with AQP4-IgG positive neuromyelitis optica spectrum disorder.2022Frontiers in immunologyFree full text
  8. Update on glial antibody-mediated optic neuritis.2022Japanese journal of ophthalmology
  9. Bilateral parafalcine cortical and leptomeningeal impairment in MOG antibody disease and AQP4 neuromyelitis optica.2022Journal of neuroimmunology
  10. Lower motor neuron involvement in patients with neuromyelitis optica spectrum disorders.2022Multiple sclerosis and related disorders
  11. The efficacy of therapeutic apheresis in patients with refractory neuromyelitis optica spectrum disorders: a single-center retrospective study.2021Annals of palliative medicine
  12. Research and progress on biomarkers of neuromyelitis optica spectrum disorders.2021Journal of receptor and signal transduction research
Chinese-language papers (not in the count)2
  1. [Correlation of cognitive function with intracranial lesions and the degree of depression and anxiety in patients with neuromyelitis optica spectrum disorders].2023Zhonghua nei ke za zhi
  2. [Analysis of the clinical characteristics and misdiagnosis of area postrema syndrome manifesting as intractable nausea, vomiting, and hiccups in neuromyelitis optica spectrum disorders].2023Zhonghua nei ke za zhi
All its trials on ClinicalTrials.gov, any status6
  1. Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World StudyRecruitingNCT07410039Lead sponsorPhase 4Start 2026-02
  2. The Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder.Not yet recruitingNCT07592754Lead sponsorEarly phase 1Start 2026-05
  3. Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20WithdrawnNCT03605238Lead sponsorPhase 1Start 2018-08
  4. Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum DisordersStatus unknownNCT02836327Lead sponsorStart 2014-09
  5. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)RecruitingNCT06413654Study sitePhase 2/Phase 3Start 2024-07
  6. A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum DisordersActive, not recruitingNCT06044350Study sitePhase 2Start 2023-08
More papers found outside PubMed (not counted)4
  1. Case report: Neuromyelitis optica spectrum disorder in a patient presented with orbital apex syndrome2024Neuroimmunology Reportsarticle
  2. Unraveling the Complexity of Area Postrema Lesions: Insights from Neuromyelitis Optica Spectrum Disorder and Beyond2024Research Squarepreprint
  3. Optic Neuromyelitis Optica Spectrum Disease with Dizziness as the Main Clinical Manifestation2023Experts' Perspectives on Medical Advances.book-chapter
  4. Teaching NeuroImages: Cortical damage with leptomeningeal enhancement in neuromyelitis optica spectrum disorder2023Neurologyarticle

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 5 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 2.0%.

Papers led
5
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 222025

11 hospitals in Beijing for IgG4-related disease46 hospitals in China for IgG4-related disease

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07148791

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  2. Not yet recruiting
    Efficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease
    Phase
    Phase 3
    Started
    2026-08
    Registry
    NCT07719543

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  3. Recruiting
    A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
    Phase
    Phase 1
    Started
    2025-05
    Registry
    NCT06978647

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis & look-alikesPancreas & bile ductsHead, eye socket & salivary glands
Departments in papersRheumatology & immunologyOphthalmology / neuro-ophthalmology
Papers it led5
  1. Clinical phenotypes and prognosis of IgG4-RD patients with allergy history: A retrospective cohort study.2026Clinical rheumatology
  2. The co-occurrence of IgG4-related disease and malignancy: insights from a prospective cohort study.2025Clinical and experimental rheumatology
  3. Assessing IgG4-related autoimmune pancreatitis with contrast-enhanced ultrasonography based on time-intensity curve: a single-centre prospective study.2025Clinical and experimental rheumatology
  4. A case of IgG4-related ophthalmic disease after SARS-CoV-2 vaccination: case report and literature review.2024Frontiers in immunologyFree full text
  5. Clinical value of plasmablasts in predicting disease relapse in patients with IgG4-related disease.2023Clinical rheumatology
Chinese-language papers (not in the count)2
  1. [Diagnosis and treatment of subglottic mass(report of 5 cases)].2024Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgeryFree full text
  2. [IgG4-related ophthalmic disease: three-case report].2021[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
All its trials on ClinicalTrials.gov, any status5
  1. Efficacy and Safety of Lenalidomide in Patients With IgG4-Related DiseaseNot yet recruitingNCT07719543Lead sponsorPhase 3Start 2026-08
  2. Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related DiseaseRecruitingNCT07148791Lead sponsorPhase 2Start 2025-09
  3. Leflunomide for Maintenance of Remission in IgG4 Related DiseaseCompletedNCT02703194Lead sponsorPhase 4Start 2016-03
  4. A Clinical Study of YTS109 Cell in R/R Autoimmune DiseasesRecruitingNCT06978647Study sitePhase 1Start 2025-05
  5. A Phase 3 Study of Obexelimab in Patients With IgG4-Related DiseaseActive, not recruitingNCT05662241Study sitePhase 3Start 2023-01

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 4 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.8%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 0020242025: 112025

11 hospitals in Beijing for myasthenia gravis93 hospitals in China for myasthenia gravis

No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesAntibodies & diagnosis
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 46 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 12.9%.

Papers led
46
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 8820212022: 2220222023: 8820232024: 151520242025: 12122025

8 hospitals in Beijing for moyamoya disease47 hospitals in China for moyamoya disease

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    The Evolution and Prognosis of Moyamoya Disease
    Phase
    Not given
    Started
    2022-09
    Registry
    NCT05619068

    Age 10 years to 60 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  2. Recruiting
    Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07894107

    Age 12 years to 70 years (registered criteria)

    Led by Beijing Tiantan Hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanchang, Shanghai, Suzhou, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & blood flowStroke & bleeding outcomesRevascularisation surgery
Departments in papersNeurosurgeryRadiology / nuclear medicine
Papers it led46
  1. Champagne bottle neck sign predicts intracranial hemorrhage in Moyamoya disease: A long-term follow-up study.2026Clinical neurology and neurosurgery
  2. The Clinical and Neuroimaging Factors of Stroke Outcome of Unilateral Moyamoya Disease.2025Academic radiology
  3. The Role of TCD in Assessing Postoperative Collateral Development and Long-Term Clinical Outcome in Moyamoya Disease.2025CNS neuroscience & therapeuticsFree full text
  4. Effects of antiplatelet therapy on reducing stroke risk in patients with moyamoya disease: the role of postcontrast MR vessel wall imaging.2025European radiology
  5. Preoperative hemorrhagic risk stratification in pediatric moyamoya disease: a multi-institutional propensity score-matched analysis.2025International journal of surgery (London, England)Free full text
  6. Treatment for moyamoya disease with hyperhomocysteinemia.2025Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and MetabolismFree full text
  7. Multi-omic serum analysis reveals ferroptosis pathways and diagnostic molecular signatures associated with Moyamoya diseases.2025Journal of neuroinflammationFree full text
  8. Long-Term Outcomes in Patients With Hemorrhagic Moyamoya Disease Combined With Hypertension After Encephaloduroarteriosynangiosis.2025Journal of the American Heart AssociationFree full text
  9. Noninvasive Assessment of the Risk Features of Hemorrhage in Moyamoya Disease Using 7T MRI.2025NeurologyFree full text
  10. Clinical significance of postoperative collateral circulation formation in long-term prognosis and stroke events after EDAS in adults with moyamoya disease.2025Neurosurgical review
  11. Optimizing Surgical Timing to Reduce Stroke Risk in Pediatric Moyamoya Disease.2025Stroke
  12. Nomogram for Predicting Long-term Outcomes of Encephaloduroarteriosynangiosis in Toddlers with Moyamoya Disease: a Longitudinal and Cross-sectional Study.2025Translational stroke research
  13. Global Hotspots and Research Frontiers of Moyamoya Disease and Radiological Features: A Bibliometric Analysis.2025World neurosurgery
  14. Imaging Assessments and Clinical Significance of Brain Frailty in Moyamoya Disease.2024AJNR. American journal of neuroradiologyFree full text
  15. Comparing Outcomes of Moyamoya Disease and Moyamoya Syndrome in a Real-World Scenario: A Cohort Study.2024CNS neuroscience & therapeuticsFree full text
  16. HAPLN3 p.T34A contributes to incomplete penetrance of moyamoya disease in Chinese carrying RNF213 p.R4810K.2024European journal of neurologyFree full text
  17. High-resolution MRI vessel wall enhancement in moyamoya disease: risk factors and clinical outcomes.2024European radiology
  18. Exploring the transcriptomic landscape of moyamoya disease and systemic lupus erythematosus: insights into crosstalk genes and immune relationships.2024Frontiers in immunologyFree full text
  19. The Association of Heterozygous p.R4810K of RNF213 and Long-Term Unfavorable Outcomes after Encephaloduroarteriosynangiosis in Chinese Pediatric Patients with Moyamoya Disease.2024Human mutationFree full text
  20. The Characteristics of Extracranial Internal Carotid Artery and Their Relationship With Surgical Outcomes in Patients With Moyamoya Disease: A Combined Head-and-Neck Vessel Wall MR Imaging Study.2024Journal of magnetic resonance imaging : JMRI
  21. Predictors of Stroke Outcomes in Conservatively Treated Patients With Moyamoya Disease: A Follow-up MRI Study.2024Journal of magnetic resonance imaging : JMRI
  22. Development and validation of a novel nomogram for predicting long-term rebleeding risk among patients with hemorrhagic moyamoya disease: a 10-year multicenter retrospective cohort study.2024Journal of neurosurgery
  23. Association between polymorphism in the MTHFR gene and encephaloduroarteriosynangiosis-induced collateral circulation formation.2024Journal of neurosurgery
  24. Long-term outcomes after conservative and EDAS treatment for 111 elderly patients with moyamoya disease: longitudinal and cross-sectional study.2024Journal of neurosurgery
  25. Risk Factors for Massive Cerebral Infarction in Pediatric Patients With Moyamoya Disease.2024Pediatric neurology
  26. Isolated anterior cerebral artery occlusion: an atypical form of moyamoya disease.2024Stroke and vascular neurologyFree full text
  27. Factors Influencing Collateral Circulation Formation After Indirect Revascularization for Moyamoya Disease: a Narrative Review.2024Translational stroke research
  28. Risk Factors for Preoperative Cerebral Infarction in Infants with Moyamoya Disease.2024Translational stroke research
  29. Proteomic and metabolomic characterizations of moyamoya disease patient sera.2023Brain and behaviorFree full text
  30. Surgical outcomes following encephaloduroarteriosynangiosis in moyamoya disease associated with hyperhomocysteinemia.2023Brain and behaviorFree full text
  31. The diagnostic performance of high-resolution magnetic resonance-vessel wall imaging in differentiating atherosclerosis-associated moyamoya vasculopathy from moyamoya disease.2023European radiology
  32. Vessel wall enhancement as a predictor of arterial stenosis progression and poor outcomes in moyamoya disease.2023European radiology
  33. Association of cognitive function and hypoperfusion in Moyamoya disease patients without stroke.2023Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and MetabolismFree full text
  34. Long-term outcomes of moyamoya disease versus atherosclerosis-associated moyamoya vasculopathy using high-resolution MR vessel wall imaging.2023Journal of neurology, neurosurgery, and psychiatry
  35. A long-term study of posterior circulation changes after revascularization in patients with moyamoya disease.2023Journal of neurosurgery
  36. Wavelet Analysis of Cerebral Oxygenation Signal Measured by Near-Infrared Spectroscopy in Moyamoya Disease.2023World neurosurgery
  37. Changes in sensory-related brain networks of patients with moyamoya disease with limb paresthesia: A resting-state fMRI-based functional connectivity analysis.2022NeuroImage. ClinicalFree full text
  38. Dynamic Changes of Collateral Vessels After Encephaloduroarteriosynangiosis in Moyamoya Disease: Childhood to Adulthood.2022World neurosurgery
  39. Ivy Sign in Moyamoya Disease: A Comparative Study of the FLAIR Vascular Hyperintensity Sign Against Contrast-Enhanced MRI.2021AJNR. American journal of neuroradiologyFree full text
  40. Association of intracranial vessel wall enhancement and cerebral hemorrhage in moyamoya disease: a high-resolution magnetic resonance imaging study.2021Journal of neurology
  41. Predictors of neoangiogenesis after indirect revascularisation in moyamoya disease: a 10-year follow-up study.2021Journal of neurology, neurosurgery, and psychiatry
  42. Validation and Extension Study Exploring the Role of RNF213 p.R4810K in 2,877 Chinese Moyamoya Disease Patients.2021Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
  43. Clinical and Genetic Risk Factors of Long-Term Outcomes after Encephaloduroarteriosynangiosis in Moyamoya Disease in China.2021Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
  44. The role of atorvastatin in collateral circulation formation induced by encephaloduroarteriosynangiosis: a prospective trial.2021Neurosurgical focus
  45. Proteomic Profiling of Exosomes From Hemorrhagic Moyamoya Disease and Dysfunction of Mitochondria in Endothelial Cells.2021Stroke
  46. Endothelial Progenitor Cells Induce Angiogenesis: a Potential Mechanism Underlying Neovascularization in Encephaloduroarteriosynangiosis.2021Translational stroke research
All its trials on ClinicalTrials.gov, any status7
  1. The Evolution and Prognosis of Moyamoya DiseaseRecruitingNCT05619068Lead sponsorStart 2022-09
  2. Predicative Value of Multimodal MRI in Moyamoya DiseaseStatus unknownNCT03785171Lead sponsorStart 2018-09
  3. Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya SyndromeRecruitingNCT07894107Study siteStart 2026-08
  4. Safety and Efficacy of RIC in Pediatric Moyamoya Disease Patients Treated With Revascularization TherapyStatus unknownNCT03546309Study siteN/AStart 2024-09
  5. Safety and Efficacy of Remote Ischemic Conditioning Combined EDAS on Ischemic Moyamoya DiseaseStatus unknownNCT04917003Study siteN/AStart 2021-06
  6. Effect of Surgical Revascularization on Hemorrhagic Moyamoya DiseaseStatus unknownNCT03627975Study siteN/AStart 2017-10
  7. Relationship Between Endothelial Progenitor Cells and Revascularization Effect of Moyamoya DiseaseStatus unknownNCT03613701Study siteStart 2017-09
More papers found outside PubMed (not counted)3
  1. Abstract 110: Pre-Operative Risks of Major Adverse Cerebrovascular Events in Pediatric Moyamoya Disease2024Strokeconference-abstract
  2. Chinese moyamoya disease study:cohort profile2023medRxivpreprint
  3. Cohort profile: Chinese moyamoya disease cohort study2023Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led no English-language PubMed papers on anti-NMDA receptor encephalitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

13 hospitals in Beijing for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

30 hospitals in Beijing for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Carotid contrast-enhanced ultrasonographic assessment of disease activity in Takayasu arteritis.2019European heart journal. Cardiovascular Imaging

Run the PubMed searchClinicalTrials.gov

Other diseases

Hepatic echinococcosis

肝包虫病

Led 2 of the 152 English-language PubMed papers on hepatic echinococcosis with an author in mainland China, 2021–2025: 1.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

6 hospitals in Beijing for hepatic echinococcosis49 hospitals in China for hepatic echinococcosis

No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 3 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 002025

27 hospitals in Beijing for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病

Led 1 of the 45 English-language PubMed papers on lymphangioleiomyomatosis with an author in mainland China, 2021–2025: 2.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

5 hospitals in Beijing for lymphangioleiomyomatosis28 hospitals in China for lymphangioleiomyomatosis

No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 20 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 2.6%.

Papers led
20
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 2220222023: 3320232024: 9920242025: 112025

19 hospitals in Beijing for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurologyGastroenterology / hepatologyRadiology / nuclear medicine
Papers it led20
  1. The difference between cystatin C- and creatinine-based estimated glomerular filtration rate and survival in amyotrophic lateral sclerosis: a population-based cohort study.2026Neurodegenerative disease management
  2. Diagnostic value of EMG of sternocleidomastoid and trapezius in assessing bulbar lower motor neuron involvement in amyotrophic lateral sclerosis patients.2025Journal of electromyography and kinesiology : official journal of the International Society of Electrophysiological Kinesiology
  3. Alterations in regional homogeneity and functional connectivity in the cerebellum of patients with sporadic amyotrophic lateral sclerosis.2024Behavioural brain research
  4. Quantitative association between lead exposure and amyotrophic lateral sclerosis: a Bayesian network-based predictive study.2024Environmental health : a global access science source
  5. Fecal microbiota transplantation significantly improved respiratory failure of amyotrophic lateral sclerosis.2024Gut microbes
  6. Mangiferin activates the nuclear factor erythroid 2-related factor pathway to protect SOD1-G93A induced NSC-34 motor neurons from oxidative stress and apoptosis.2024Journal of biochemical and molecular toxicology
  7. Prognostic Value of Systemic Inflammation, Nutritional Status and Sarcopenia in Patients With Amyotrophic Lateral Sclerosis.2024Journal of cachexia, sarcopenia and muscle
  8. Prognostic value of geriatric nutritional risk index in patients with amyotrophic lateral sclerosis.2024Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  9. Mendelian Randomization Identifies Genetically Supported Drug Targets for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.2024Molecular neurobiology
  10. Quantitative evaluation of factors influencing the 3 Hz repetitive nerve stimulation test in patients with amyotrophic lateral sclerosis.2024Muscle & nerve
  11. Serum Cystatin C is a potential biomarker for predicting amyotrophic lateral sclerosis survival.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  12. Myasthenia gravis with amyotrophic lateral sclerosis with positive anti-Hu antibody: a rare co-existence.2023Acta neurologica Belgica
  13. Gender-specific association of uric acid and survival in sporadic amyotrophic lateral sclerosis patients.2023Brain research
  14. Evaluating the causal association between microRNAs and amyotrophic lateral sclerosis.2023Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  15. Clinical heterogeneity in a family with flail arm syndrome and review of hnRNPA1-related spectrum.2022Annals of clinical and translational neurology
  16. Time of symptoms beyond the bulbar region predicts survival in bulbar onset amyotrophic lateral sclerosis.2022Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  17. Genetic and clinical features of Chinese sporadic amyotrophic lateral sclerosis patients with TARDBP mutations.2021Brain and behavior
  18. Inflammatory Cytokine Levels in Patients with Sporadic Amyotrophic Lateral Sclerosis.2021Neuro-degenerative diseases
  19. Characteristics of Late-Onset Amyotrophic Lateral Sclerosis in a Chinese Cohort.2021Neuro-degenerative diseases
  20. Quantitative susceptibility-weighted imaging in amyotrophic lateral sclerosis with 3.0 T magnetic resonance imaging.2021The Journal of international medical research
Chinese-language papers (not in the count)4
  1. [Analysis of serum 25-hydroxyvitamin D3 levels and prognosis in patients with amyotrophic lateral sclerosis].2025Zhonghua nei ke za zhi
  2. [Progression patterns of lower motor neuron involvement in the lower medulla oblongata and cervical spinal cord of amyotrophic lateral sclerosis patients].2025Zhonghua yi xue za zhi
  3. [Analysis of the characteristics of patients with amyotrophic lateral sclerosis with neuromuscular junction dysfunction prior to motor neuron degeneration].2024Zhonghua nei ke za zhi
  4. [Analysis of disease progression rate and related factors in amyotrophic lateral sclerosis patients at initial visit].2022Zhonghua yi xue za zhi
Earlier papers (2016–2020)23
  1. UCHL1 from serum and CSF is a candidate biomarker for amyotrophic lateral sclerosis.2020Annals of clinical and translational neurology
  2. The increase in CSF total protein and immunoglobulins in Chinese patients with sporadic amyotrophic lateral sclerosis: A retrospective study.2020Journal of the neurological sciences
  3. Medical cost and healthcare utilization of amyotrophic lateral sclerosis in China: A cohort study based on hospital data from 2015 to 2018.2020Medicine
  4. Efficient and rapid conversion of human astrocytes and ALS mouse model spinal cord astrocytes into motor neuron-like cells by defined small molecules.2020Military Medical Research
  5. Elevated serum ferritin level as a predictor of reduced survival in patients with sporadic amyotrophic lateral sclerosis in China: a retrospective study.2019Amyotrophic lateral sclerosis & frontotemporal degeneration
  6. Prognostic value of time to generalization in 71 Chinese patients with sporadic amyotrophic lateral sclerosis.2019Chinese medical journal
  7. A novel D90_K91insN mutation in exon 4 of the SOD1 gene caused familial amyotrophic lateral sclerosis in a Chinese pedigree.2018Amyotrophic lateral sclerosis & frontotemporal degeneration
  8. Screening for possible oligogenic pathogenesis in Chinese sporadic ALS patients.2018Amyotrophic lateral sclerosis & frontotemporal degeneration
  9. Repetitive Nerve Stimulation in Amyotrophic Lateral Sclerosis.2018Chinese medical journal
  10. Cortical Thinning Pattern of Bulbar- and Spinal-onset Amyotrophic Lateral Sclerosis: a Surface-based Morphometry Study.2018Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  11. Gray Matter Volume Changes over the Whole Brain in the Bulbar- and Spinal-onset Amyotrophic Lateral Sclerosis: a Voxel-based Morphometry Study.2018Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  12. The efficacy and safety of riluzole for neurodegenerative movement disorders: a systematic review with meta-analysis.2018Drug delivery
  13. Cutaneous somatic and autonomic nerve TDP-43 deposition in amyotrophic lateral sclerosis.2018Journal of neurology
  14. Therapeutic effects of percutaneous endoscopic gastrostomy on survival in patients with amyotrophic lateral sclerosis: A meta-analysis.2018PloS one
  15. Chemical conversion of human and mouse fibroblasts into motor neurons.2018Science China. Life sciences
  16. [Screening of the SETX gene in sporadic amyotrophic lateral sclerosis patients of Chinese origin].2018Zhonghua yi xue za zhi
  17. 18F-fallypride PET-CT of dopamine D2/D3 receptors in patients with sporadic amyotrophic lateral sclerosis.2017Journal of the neurological sciences
  18. [Characteristics of repetitive nerve stimulation in 53 cases of amyotrophic lateral sclerosis].2017Zhonghua yi xue za zhi
  19. Phosphorylated neurofilament heavy chain levels in paired plasma and CSF of amyotrophic lateral sclerosis.2016Journal of the neurological sciences
  20. A novel 10-base pair insertion mutation in exon 5 of the SOD1 gene in a Chinese family with amyotrophic lateral sclerosis.2016Neurobiology of aging
  21. Treatment with Hydrogen-Rich Saline Delays Disease Progression in a Mouse Model of Amyotrophic Lateral Sclerosis.2016Neurochemical research
  22. [An analysis of characteristics of nerve conduction in 154 cases of amyotrophic lateral sclerosis].2016Zhonghua nei ke za zhi
  23. [Needle electromyography features and values of paraspinal muscle parameters in assessment of respiratory function of patients with amyotrophic lateral sclerosis].2016Zhonghua yi xue za zhi

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led 2 of the 55 English-language PubMed papers on spinal muscular atrophy with an author in mainland China, 2021–2025: 3.6%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

8 hospitals in Beijing for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06971094

    Age 2 years to 12 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Shenzhen, Suzhou, Wuhan

  2. Recruiting
    Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Registry
    NCT05824169

    Age 0 months to 6 months (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shenyang, Suzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led 3 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 4.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

11 hospitals in Beijing for Fabry disease85 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Pompe disease

庞贝病

Led 1 of the 30 English-language PubMed papers on Pompe disease with an author in mainland China, 2021–2025: 3.3%.

Papers led
1
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

6 hospitals in Beijing for Pompe disease30 hospitals in China for Pompe disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Evaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy Drug
    Phase
    Phase 1/Phase 2
    Started
    2024-04
    Registry
    NCT06391736

    Age 6 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPediatricsNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 5 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 2.4%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 332025

11 hospitals in Beijing for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led5
  1. Association between triglycerides and remnant cholesterol levels and spine bone mineral density in Duchenne muscular dystrophy.2025Lipids in health and disease
  2. Generation and differentiation of an induced pluripotent stem cell line (FMCPGHi006-A) from a patient with Duchenne muscular dystrophy carrying exons 42-43 deletion in the DMD gene.2025Stem cell research
  3. Mechanisms of cardiomyopathy in duchenne muscular dystrophy: A study using pluripotent stem cells derived from patients with severe and mild motor impairment.2025Tissue & cell
  4. Current care practices for patients with Duchenne muscular dystrophy in China.2022Brain & development
  5. Genotype characterization and delayed loss of ambulation by glucocorticoids in a large cohort of patients with Duchenne muscular dystrophy.2021Orphanet journal of rare diseases
Earlier papers (2016–2020)2
  1. Prenatal diagnosis of Duchenne muscular dystrophy revealed a novel mosaic mutation in Dystrophin gene: a case report.2020BMC medical genetics
  2. Genetic ablation of P65 subunit of NF-κB in mdx mice to improve muscle physiological function.2017Muscle & nerve
All its trials on ClinicalTrials.gov, any status3
  1. Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53)CompletedNCT04956289Study sitePhase 2Start 2021-07
  2. Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)Active, not recruitingNCT04768062Study sitePhase 3Start 2021-04
  3. Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)CompletedNCT04060199Study sitePhase 3Start 2020-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

24 hospitals in Beijing for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Chinese-language papers (not in the count)1
  1. [Analysis of the clinical characteristics of 25 cases with parenchymal neuro-Behcet's disease].2023Zhonghua nei ke za zhi

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led 1 of the 58 English-language PubMed papers on Alport syndrome with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

7 hospitals in Beijing for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 17 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 2.3%.

Papers led
17
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 1120222023: 2220232024: 5520242025: 662025

32 hospitals in Beijing for IgA nephropathy346 hospitals in China for IgA nephropathy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Early Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.
    Phase
    Not given
    Started
    2025-10
    Registry
    NCT07585981

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNephrologyRadiology / nuclear medicineOphthalmology / neuro-ophthalmology
Papers it led17
  1. Development and validation of a single-nephron estimated glomerular filtration rate model to predict disease progression in IgA nephropathy.2025BMC nephrology
  2. C3 glomerulopathy associated with mycoplasma pneumoniae infection and positive IgA staining.2025BMC nephrology
  3. Urine Metabolomics Reveals the Intervention Effects and Mechanism of Shenhua Tablets in IgA Nephropathy.2025Biomedical chromatography : BMC
  4. IKZF1 as a potential therapeutic target for dendritic cell-mediated immunotherapy in IgA nephropathy.2025Cell communication and signaling : CCS
  5. A multi-task deep sequential neural network for IgA nephropathy Oxford classification and prognosis prediction.2025International journal of medical informatics
  6. Spatially resolved multi-omics reveals the renal cortex-metabolic reprogramming of Shenhua Tablet for intervention on IgA nephropathy.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  7. Serum levels of sonic hedgehog in patients with IgA nephropathy are closely associated with intrarenal arteriolar lesions.2024Clinical biochemistry
  8. External Validation of the International IgA Nephropathy Prediction Tool in Older Adult Patients.2024Clinical interventions in aging
  9. Urinary miR-185-5p is a biomarker of renal tubulointerstitial fibrosis in IgA nephropathy.2024Frontiers in immunology
  10. Cross-species single-cell analysis uncovers the immunopathological mechanisms associated with IgA nephropathy progression.2024JCI insight
  11. Identification of common and specific fibrosis-related genes in three common chronic kidney diseases.2024Renal failure
  12. Clinical relevance of glomerular C4d deposition in children with early IgA nephropathy or Henoch-Schönlein purpura nephropathy.2023Pediatric nephrology (Berlin, Germany)
  13. Urinary miR-16-5p can be used as a potential marker of endocapillary hypercellularity in IgA nephropathy.2023Scientific reports
  14. Contrast-enhanced ultrasonography for assessing histopathology in pediatric immunoglobulin A nephropathy and Henoch-Schönlein purpura nephritis.2022Pediatric radiology
  15. Serum levels of galactose-deficient IgA1 in Chinese children with IgA nephropathy, IgA vasculitis with nephritis, and IgA vasculitis.2021Clinical and experimental nephrology
  16. Association of Immune and Inflammatory Gene Polymorphism With the Risk of IgA Nephropathy: A Systematic Review and Meta-Analysis of 45 Studies.2021Frontiers in immunology
  17. Urinary sediment microRNAs can be used as potential noninvasive biomarkers for diagnosis, reflecting the severity and prognosis of diabetic nephropathy.2021Nutrition & diabetes
Chinese-language papers (not in the count)2
  1. [The value of T1 mapping in the non-invasive assessment of the Oxford classification of IgA nephropathy].2025Zhonghua nei ke za zhi
  2. [Validation and comparison of diabetic retinopathy-based diagnostic models for diabetic nephropathy].2023Nan fang yi ke da xue xue bao = Journal of Southern Medical University
Earlier papers (2016–2020)21
  1. Potential value of three-dimensional ultrasonography in diagnosis of diabetic nephropathy in Chinese diabetic population with kidney injury.2020BMC nephrology
  2. Single-Cell Transcriptomics Reveal Immune Mechanisms of the Onset and Progression of IgA Nephropathy.2020Cell reports
  3. Relationship between serum C3/C4 ratio and prognosis of immunoglobulin A nephropathy based on propensity score matching.2020Chinese medical journal
  4. Eosinophilic fasciitis associated with generalized morphea and IgA nephropathy.2020Dermatologic therapy
  5. Influences of renal anemia on the pathology of IgA nephropathy: a study based on propensity score matching.2020Discovery medicine
  6. Urinary angiostatin: a novel biomarker of kidney disease associated with disease severity and progression.2019BMC nephrology
  7. Clinical and pathological factors of renal anaemia in patients with IgA nephropathy in Chinese adults: a cross-sectional study.2019BMJ open
  8. A non-invasive diagnostic model of immunoglobulin A nephropathy and serological markers for evaluating disease severity.2019Chinese medical journal
  9. Predictive Capabilities of Three Widely Used Pathology Classification Systems and a Simplified Classification (Beijing Classification) in Primary IgA Nephropathy.2019Kidney & blood pressure research
  10. A pilot and comparative study between pathological and serological levels of immunoglobulin and complement among three kinds of primary glomerulonephritis.2018BMC immunology
  11. Clinicopathological Features of Nondiabetic Renal Diseases from Different Age Groups: An Observational Cross-sectional Study.2018Chinese medical journal
  12. Potential Blood Pressure Goals in IgA Nephropathy: Prevalence, Awareness, and Treatment Rates in Chronic Kidney Disease Among Patients with Hypertension in China (PATRIOTIC) Study.2018Kidney & blood pressure research
  13. U6 can be used as a housekeeping gene for urinary sediment miRNA studies of IgA nephropathy.2018Scientific reports
  14. Urinary sediment miRNAs reflect tubulointerstitial damage and therapeutic response in IgA nephropathy.2017BMC nephrology
  15. Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis.2017BMC nephrology
  16. Comparative proteomic analysis of urine and laser microdissected glomeruli in IgA nephropathy.2017Clinical and experimental pharmacology & physiology
  17. Urinary Erythrocyte-Derived miRNAs: Emerging Role in IgA Nephropathy.2017Kidney & blood pressure research
  18. Decreased Serum C3 Levels in Immunoglobulin A (IgA) Nephropathy with Chronic Kidney Disease: A Propensity Score Matching Study.2017Medical science monitor : international medical journal of experimental and clinical research
  19. Abelmoschus manihot - a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy: study protocol for a randomized controlled trial.2017TrialsRCT
  20. Efficacy of Leflunomide, Telmisartan, and Clopidogrel for Immunoglobulin A Nephropathy: A Randomized Controlled Trial.2016Chinese medical journalRCT
  21. Selection of urinary sediment miRNAs as specific biomarkers of IgA nephropathy.2016Scientific reports
All its trials on ClinicalTrials.gov, any status4
  1. Early Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.RecruitingNCT07585981Lead sponsorStart 2025-10
  2. TESTING -ON Post-Trial ObservatioNal Cohort StudyCompletedNCT05434325Study siteStart 2022-12
  3. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09
  4. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)CompletedNCT01560052Study siteN/AStart 2012-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Gaucher disease

戈谢病

Led 1 of the 30 English-language PubMed papers on Gaucher disease with an author in mainland China, 2021–2025: 3.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

5 hospitals in Beijing for Gaucher disease41 hospitals in China for Gaucher disease

No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics
Papers it led1
  1. Update of treatment for Gaucher disease.2022European journal of pharmacology
Chinese-language papers (not in the count)1
  1. [Advances in the specific treatments of Gaucher disease].2024Zhonghua nei ke za zhi
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher DiseaseCompletedNCT05529992Study sitePhase 3Start 2023-01

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led no English-language PubMed papers on osteogenesis imperfecta in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Beijing for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 2 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

16 hospitals in Beijing for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology
Papers it led2
  1. MicroRNA-126-3p as a predictive biomarker for patients with primary biliary cholangitis refractory to ursodeoxycholic acid.2025World journal of gastroenterology
  2. Letter to the Editor: Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome-First report of the IAIHG retrospective registry.2024Hepatology (Baltimore, Md.)
Chinese-language papers (not in the count)2
  1. [Value of autocrine motility factors in the prediction of the disease progression of PBC- associated hepatocellular carcinoma].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  2. [Immune pathogenesis of primary biliary cholangitis].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
Earlier papers (2016–2020)2
  1. Treatment of primary biliary cirrhosis with ursodeoxycholic acid combined with traditional Chinese medicine: A protocol for systematic review and meta analysis.2020Medicine
  2. [Clinicopathological features of early- and late-stage primary biliary cirrhosis: a comparative study].2016Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
All its trials on ClinicalTrials.gov, any status5
  1. Phase I/II Trial of Human Umbilical Cord Mesenchymal Stromal Cells for UDCA-Refractory Primary Biliary CholangitisNot yet recruitingNCT07795151Lead sponsorPhase 1/Phase 2Start 2026-08
  2. Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCAWithdrawnNCT02965911Lead sponsorPhase 1/Phase 2Start 2016-01
  3. Umbilical Cord Mesenchymal Stem Cells for Patients With Primary Biliary CirrhosisStatus unknownNCT01662973Lead sponsorPhase 1/Phase 2Start 2011-10
  4. Performance of Scoring Systems in Chinese Patients With Primary Biliary Cholangitis (PBC) on Ursodeoxycholic AcidCompletedNCT03188146Study siteStart 2017-05
  5. Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary CirrhosisCompletedNCT01857284Study sitePhase 3Start 2009-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

7 hospitals in Beijing for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Leber hereditary optic neuropathy

Leber 遗传性视神经病变

Led 1 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 1.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

3 hospitals in Beijing for Leber hereditary optic neuropathy32 hospitals in China for Leber hereditary optic neuropathy

No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

中国人民解放军总医院

Chinese PLA General Hospital

北京

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Chinese People's Liberation Army General Hospital; First Medical Center of Chinese PLA General Hospital; Fifth Medical Center of PLA General Hospital; PLA General Hospital; Fifth Medical Center of Chinese PLA General Hospital; PLA Army General Hospital; 301 Military Hospital; PLAGH

Suggest a correctionDownload the data